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ABSTRACT 
Older adults with peripheral arterial disease (PAD) can experience 
impairments in both functional capacity (FC) and functional performance (FP). Few 
studies have examined the effect of PAD severity on FC and FP utilizing a latent 
variable model. The purpose of this secondary analysis of the National Health and 
Nutrition Examination Survey (NHANES) 1999 – 2002 survey cycles was to develop 
and test a latent variable model of FC and FP in older adults with and without PAD.  
The study sample included a subpopulation of all NHANES participants from 
the 1999-2002 survey cycles (N = 21,004) over the age of 50 years (n = 3695) who 
had screening performed for PAD. Subjects were then separated into a ‘no PAD’ (n 
= 3317) and ‘PAD’ (n = 378) group for analysis. Measures included ankle-brachial 
index (PAD severity), maximum calf circumference, quadriceps strength (lower 
extremity strength), Semmes-Weinstein monofilament test (lower extremity sensory 
impairment), 20-foot timed walk (usual gait speed), self-reported level of physical 
activity, and physical function questionnaire (ability to perform routine daily tasks).  
Analyses included multigroup confirmatory factor analysis (MG-CFA) of the 
measurement model, structural equation modeling, and indirect effect testing. The  
MG-CFA of the measurement model demonstrated configural, metric, and scalar 
invariance between the ‘no PAD’ and ‘PAD’ groups. Multigroup structural equation 
modeling demonstrated acceptable fit of the model to the data controlling for PAD 
severity, age, and gender (RMSEA 0.058, CFI 0.811, and SRMR 0.069). The fit was 
also acceptable after controlling for PAD severity, age, gender, and diabetes 
(RMSEA 0.059, CFI 0.782, and SRMR 0.069). Indirect effect testing showed FC to 
xv 
mediate the relationship between PAD severity and FP in the ‘PAD’ group. These 
findings support the applicability of a latent variable model for evaluating the effect of 
PAD severity on FC and FP in older adults with PAD.  
  1 
CHAPTER I 
INTRODUCTION 
 This dissertation examines a latent variable model of functional capacity 
(FC) and functional performance (FP) in a group of older adults with and without 
peripheral arterial disease (PAD). It will identify and evaluate the relationships 
between PAD severity and latent variables FC and FP. It will show that past 
research on PAD severity and function has yielded inconclusive and inconsistent 
results regarding these relationships. Additionally, it will show that past research 
has not provided a plausible model of the processes that explain function in older 
adults with PAD. This dissertation will utilize a secondary data analysis of the 
National Health and Nutrition Examination Survey (NHANES) to test a plausible 
latent variable model of FC and FP in a subpopulation of the survey with no PAD 
and with PAD.  
Prevalence of PAD 
Peripheral arterial disease (PAD) affects 8-12 million people in the United 
States and can be found in approximately 12-35% of adults over the age of 55 
years (Hirsch, et al., 2001). There is increased risk for concomitant coronary 
artery disease (14-90%) and cerebrovascular disease (25%) in older adults with 
PAD (Golomb, Dang, & Criqui, 2006). Furthermore, PAD is associated with an 
increased risk of death and disability from cardiovascular disease (Newman, 
Sutton-Tyrrell, Vogt, & Kuller, 1993). All-cause mortality is also increased 
(Resnick, Lindsay, McDermott, Devereaux, Jones, & Fabsitz, et al, 2004).  
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Global Burden of Disease 
The World Health Organization (WHO) report on disability-adjusted life 
years provides a tangible measure of the loss of health associated with human 
disease (Lancet, 2012). Disability-adjusted life years (DALY) are defined as the 
sum of life years lost due to premature death and years lived with disability 
(YLD). The YLD comprises the product of the prevalence of the disease and a 
disability weight. These elements compare the current condition of population 
health to normative standards. This recent WHO report compares these metrics 
from the year 1990 to the year 2010.  
The United States prevalence of PAD is 5-12%, and the individual impact 
of this disease is striking. The WHO report states that the DALY (thousands) for 
peripheral arterial disease in 1990 was 505 (342-748). In 2010, the DALY for 
PAD was 995 (703-1445), which was a 97% increase. The YLD for PAD 
increased 63% from 1990 to 2010. It is evident that PAD results disability and the 
potential for reducing a person’s life span. These figures portray the real life 
burden of living with peripheral arterial disease. 
Living with PAD: Impact on Function 
The functional consequences of PAD are significant. Adults with PAD may 
have impairments in walking, performing daily activities, and participating in 
social activities (McDermott, Liu, Greenland, et al, 2004; McDermott, Greenland, 
Liu, et al, 2002). Specifically, impairments in sensation, strength, and gait speed 
contribute to decreased function as well as lower levels of physical activity. In 
short, PAD can affect the quality of many aspects of a person’s daily life.  
3 
Organizing Framework 
The functional status framework (FSF) is the organizing structure chosen 
to guide this study (Leidy, 1994, 1995). The FSF has been utilized to study 
functional performance in people with COPD (Leidy, 1995). A diagram of the 
framework is shown in Figure 1.1. The concepts of functional capacity and 
functional performance are utilized to create a model of functional status for this 
dissertation.   
The FSF defines functional status as a comprehensive picture of a 
person’s functioning to include all areas that contribute to health and well being 
including physical, psychological, social and spiritual needs. There are four 
specific areas of functional status according to the framework: functional 
capacity, reserve, performance, and capacity utilization. The focus of this study 
will be on functional capacity and functional performance.  
Functional capacity is defined as: “one’s maximum potential to perform 
those activities people do in the normal course of their lives to meet basic needs, 
fulfill usual roles, and maintain their health and well-being” (Leidy, 1994). 
Physical attributes of functional capacity include strength, endurance, respiratory, 
and cardiac capacity (Leidy, 1994). For this study, lower extremity strength, lower 
extremity sensory impairment, and calf circumference were used as indicators of 
functional capacity. These variables will be discussed further in the next section. 
Functional performance is defined as: “the physical, psychological, social, 
occupational, and spiritual activities that people actually do in the normal course 
4 
of their lives to meet basic needs, fulfill usual roles, and maintain their health and 
well-being” (Leidy, 1994).  
These activities are usually performed at a level that does not require or 
meet a person’s functional capacity. Activities of daily living represent the 
physical component functional performance. Social activities are those that 
involve family and friends as well as community involvement. Spiritual activities 
are those that include involvement in organized religious activities such as 
attendance at worship services. This study used physical activity, activities of 
daily living, and usual gait speed as indicators of functional performance. These 
will be discussed further in the next section.  
   100% 
Capacity 
Performance 
Figure 1.1. Functional status framework (Leidy, 1994) 
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Theoretical Model 
It was determined that a multivariate model was needed to account for the 
complexity of the process that determines functional performance in older adults 
with PAD. In addition, the goal of this multivariate model is to build upon the 
current body of knowledge in order to provide a significant contribution to the 
science. 
A latent variable model (Figure 1.2) was created for this study, guided by 
the FSF (Figure 1.1). The latent variables are functional capacity (FC) and 
functional performance (FP). The functional capacity indicators are lower 
extremity strength, calf circumference, and lower extremity sensory impairment. 
The functional performance indicators are physical activity, activities of daily 
living, and usual gait speed. 
Figure 1.2. Theoretical Model 
PAD 
SEVERITY 
FC 
FP 
6 
Study Significance 
 The severity of PAD and functional capacity can influence functional 
performance in older adults with PAD. The global and individual magnitude of 
this problem is significant as demonstrated in the data published by the WHO 
report (Lancet, 2012). Older adults living with PAD experience a loss in function 
that can affect mobility, social functioning, and ability to perform self-care and 
daily tasks. Research to date has provided a solid foundation to the underlying 
mechanisms of function in older adults with PAD, but several questions remain 
unanswered that will be addressed by this study.  
Purpose 
The purpose of this study was to determine the relationship between PAD 
severity, functional capacity and functional performance in older adults with PAD 
using a latent variable model. This model will be fit in two groups, a ‘no PAD’ 
group, and ‘PAD’ group, and compared. Age, gender, and diabetes were 
included as covariates.  
Specific Aims 
The specific aim with corresponding hypotheses for this study: 
Specific Aim 1. Develop, test, and fit a plausible latent variable (measurement 
and structural) model to explain the effect of PAD severity on functional capacity 
(FC) and functional performance (FP) in older adults with no PAD and with PAD. 
Hypothesis 1.1: The proposed latent variable model will be a good fit in 
both the no PAD and PAD groups 
7 
Hypothesis 1.2: Multigroup analysis will demonstrate measurement 
invariance of the model between the no PAD and PAD groups 
Specific Aim 2. Test the full structural model to explain the effect of PAD 
severity, age, gender and diabetes on FC and FP in older adults with and without 
PAD.  
Hypothesis 2.1: As PAD severity increases, FC and FP will decline 
 Hypothesis 2.2: As age increases, FC and FP will decline in both the no 
PAD and PAD groups 
 Hypothesis 2.3: There will be a significant difference in FC and FP 
controlling for age, gender, and diabetes in the no PAD and PAD groups 
Specific Aim 3. Perform mediation analysis on the full structural model to 
determine if FC mediates the relationship between PAD severity and FP 
Hypothesis 3.1: FC will mediate the relationship between PAD severity 
and FP in older adults with PAD 
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CHAPTER II 
BACKGROUND AND SIGNIFICANCE 
 The purpose of this section is to present the existing evidence which 
supports the relationships between the model variables. The evidence supporting 
the relationships between PAD severity, FC, and FP will be discussed.  
Relationship Between PAD Severity and Model Variables 
Peripheral arterial disease is defined as atherosclerosis of the arterial 
system of the lower extremities, including the femoral, popliteal, and tibial arteries 
(Hirsch, Criqui, Treat-Jacobson, Regensteiner, Creager, and Olin, et al., 2001). 
The presence of PAD is determined by obtaining an ankle-brachial index (ABI) of 
the lower extremity. The ankle-brachial index is the ratio between the systolic 
pressure of the ankle using the posterior tibial artery or the dorsalis pedis artery 
(whichever is highest) and the highest systolic arm pressure. A normal ABI is 
greater than 0.90, and PAD is present when the ABI is 0.90 or below (Hirsch, et 
al., 2001). The severity of PAD is documented and categorized by the value of 
the ABI. As reported in previous studies, the categories of PAD disease severity 
by ABI are: no PAD (ABI > = 0.91 and ABI < = 1.50), mild to moderate PAD (ABI 
> = 0.40 and < = 0.90), and severe PAD (ABI < = 0.39).  For the purpose of this 
study, subjects will be grouped as ‘no PAD’ as determined by an ABI > = 0.91, 
and ‘PAD’ as determined by an ABI < = 0.90. 
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PAD Disease Severity and Functional Capacity Indicators 
Figure 1.3  PAD Severity and Functional Capacity Indicators 
Lower Extremity Strength. In older adults, PAD can result in lower 
extremity strength deficits (McDermott, Criqui, Greenland, Guralnik, Liu, & 
Pearce, et al., 2005). Known mechanisms of decreased strength in older adults 
with PAD include a reduction in the number of skeletal muscle fibers in the lower 
extremities and skeletal muscle atrophy, due to decreased perfusion to the 
tissues (ischemia) (McDermott, et al., 2005). Two main studies have examined 
the relationship between PAD disease severity and lower extremity strength. 
McDermott, et al., investigated the relationship between the severity of 
PAD and lower extremity strength. A cross-sectional study of 269 subjects with 
PAD and 245 subjects without PAD was performed.  The sample was 56% male 
and the mean age was 73 years old. The severity of PAD was measured by ABI. 
The categories of PAD were none (ABI 0.91 - 1.10), mild PAD (0.70 - 0.90), 
moderate PAD (0.50 - 0.70), and severe PAD (< = 0.50). Lower extremity 
strength was measured using a musculoskeletal fitness chair, which measured 
isometric lower extremity strength in newton-meters for knee flexion/extension 
FC 
FP 
PAD 
Severity 
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and hip flexion/extension. Results demonstrated that leg strength was 
significantly lower in subjects with PAD than those without PAD for hip extension 
(61.4 vs. 71.6 newton-meters, p< .001), hip flexion (54.0 vs. 61.7 newton-meters, 
p< .001) and knee flexion (29.1 vs. 35.4 newton-meters, p< .001). A significant 
relationship was found between ABI and leg strength in hip flexion/extension and 
knee flexion/extension.  
The relationship between PAD disease severity and lower extremity 
strength was also evaluated in another study of 144 subjects with PAD (Atkins & 
Gardner, 2004). Functional performance measures of physical activity and a six-
minute walk test were included as covariates. The subjects were mostly male 
(83.3%) with an age range of 45 to 84 years old. The presence and severity of 
PAD was determined by the ABI. Mild PAD was categorized by an ABI of 0.76 -
0.90, moderate PAD was categorized by an ABI of 0.51 - 0.75, and severe PAD 
was categorized by an ABI of 0.36 - 0.50. In this study, lower extremity strength 
was measured by a chair-stand test. There was a significant difference in chair-
stand times between the moderate PAD group and the severe PAD group (13.49 
seconds vs. 15.86 seconds, p< .05). The significant difference between the 
moderate and severe PAD groups in lower extremity strength disappeared after 
controlling for FP. This suggests that additional factors other than PAD disease 
severity may contribute to the reduced lower extremity strength in subjects with 
PAD.  
Lower Extremity Sensory Impairment. Symptoms of peripheral 
neuropathy such as numbness, tingling, and foot pain can contribute to 
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impairments in functional capacity and functional performance (McDermott, Sufit, 
Nishida, Guralnik, Ferrucci, & Tian, et al., 2006). Several studies have 
documented the impairments of the peripheral nerves and muscles associated 
with PAD (McDermott, Guralnik, Albay, Bandinelli, Miniati, & Ferrucci, et al., 
2004; McDermott, et al., 2006; England, Ferguson, Hiatt & Regensteiner, 1995; 
Weinberg, Simovic, Isner, & Ropper, 2001). However, to our knowledge no 
previous studies have evaluated the relationship between PAD disease severity 
and lower extremity sensory impairment.  
Calf Circumference. Peripheral arterial disease results in the alteration of 
calf muscle characteristics (Mitchell, Duscha, Robbins, Redfern, Chung, & 
Bensimhon, et al., 2007). This includes cell death of gastrocnemius (calf) muscle 
and muscle fiber atrophy (Mitchell, et al., 2007; Regensteiner, Wolfel, Brass, 
Carry, Ringel, & Hargarten, et al., 1993). In addition, adverse metabolism in 
muscle, skeletal muscle capillary density, and alteration in oxygenation of calf 
muscle has been reported. These adverse effects are associated with muscle 
ischemia as a result of PAD (Regensteiner, et al., 1993). Calf muscle changes 
can be evaluated by measuring the calf muscle area in older adults with PAD. 
This has been documented in studies using a standard measure of calf 
circumference by measuring the calf at its largest area. Computed tomography 
has also been used to obtain more detailed information about the calf muscle 
and fat distribution in older adults with PAD (Regensteiner, et al., 1993).  
In a study of calf muscle characteristics in older adults with PAD, the 
amount of calf muscle fiber loss, type of calf muscle fiber loss, and calf 
12 
circumference (cm2) was measured. There was significant atrophy of both type I 
(slow twitch) and type II (fast twitch) fibers in calf skeletal muscle of subjects with 
PAD. The diameters of both types of fibers were reduced in older adults with 
PAD, and the authors suggested that these fiber changes likely resulted in 
decreased calf circumference in older adults with PAD. Indeed, calf 
circumference was significantly smaller in older adults with PAD compared to 
older adults without PAD (94.5cm2, SD = 18.4 vs. 99.7 cm2 , SD = 11.9, p< .05) 
(Regensteiner, et al.). In addition, there was significant reduction in calf 
circumference of at least 5% in the diseased legs when compared to non-
diseased legs. There was also a significant correlation between PAD severity 
and amount of reduction in fiber area. 
PAD Disease Severity and Functional Performance Indicators 
Figure 1.4 PAD Severity and Functional Performance Indicators 
Peripheral arterial disease has a significant impact on a person’s ability to 
perform FP activies (Dolan, Liu, Criqui, Greenland, Guralnik, & Chan, et al., 
PAD 
Severity 
FC 
FP 
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2002). Several studies that have evaluated the relationship between PAD 
disease severity and indicators of FP will be reviewed below.  
Physical Function Questionnaire (PFQ). McDermott and colleagues 
(McDermott, Mehta, Liu, Guralnik, Martin, & Criqui, et al., 1999) studied the 
relationship between PAD disease severity and indicators of FP in a group of 
adults aged 55 and older with PAD (n = 147). The sample was 55% male, with a 
mean age of 71.5 years old. The mean ABI of the group was 0.56, indicating 
moderate to severe PAD. The severity of PAD was measured by the ABI and the 
Walking Impairment Questionnaire (WIQ) measured FP. The WIQ measured 
walking distance, walking speed, and stair climbing ability in the community 
setting. Subjects were asked to report levels of difficulty associated with walking 
long distances, walking at different speeds, and walking up and down one to 
three flights of stairs. Results demonstrated that PAD disease severity as 
measured by ABI was an independent predictor of difficulty associated with 
walking distance (β= 2.73, p= .03) in patients with PAD and remained so even 
after controlling for leg symptoms, comorbidities including diabetes, and prior 
revascularization. These results describe the relationship between PAD disease 
severity and FP; more severe PAD results in worse FP.  
The severity of PAD has also been shown to predict future declines in FP 
(McDermott, Ferrucci, Simonsick, Balfour, & Fried, et al., 2002). McDermott and 
colleagues (McDermott, et al., 2002) evaluated the relationship between PAD 
disease severity and long-term reduction in FP in a group of older adult women 
(n = 257). The severity of PAD was measured by ABI and divided into two 
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groups: ABI < 0.60 (severe PAD) and ABI 0.61 - 0.90 (moderate PAD). The 
mean age of the severe PAD group was 79.8 years, and the mean age of the 
moderate PAD group was 79.5 years. Functional performance was measured as 
by self-reported ability to walk a quarter mile, the number of blocks walked in the 
previous week, and the number of stairs climbed the previous week. 
Measurements were taken at baseline and followed up with subjects being 
retested every six months for a total of three years.  Results demonstrated that 
women with severe PAD had a higher incidence of severe impairment in FP at 
the three-year follow-up. Women with severe PAD were less likely to be able to 
walk a quarter mile, more likely to walk less outside the home, and walked more 
slowly than those with less severe PAD. A lower ABI at baseline resulted in 
greater impairment in FP at three years.  
Physical Activity. Physical activity is an indicator of functional 
performance in older adults with PAD (Gardner & Clancy, 2006). It is important in 
the maintenance of health and function; however, daily levels of physical activity 
are reduced in older adults with PAD (Gardner & Clancy, 2006). The severity of 
PAD may affect the extent of decrease in levels of physical activity in older adults 
with PAD (Gardner, Killewich, Katzel, Womack, Montgomery, & Otis, 1999). 
Therefore, the relationship between PAD disease severity and physical activity is 
reviewed. 
The relationship between PAD severity and physical activity was 
examined in a group of older adults with PAD (n = 61) (Gardner, et al.,1999). The 
mean age of the participants was 70 years old and the sample was mostly male 
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(93%). Physical activity was measured by the “Energy Expenditure Physical 
Activity (EEPA),” which is determined by double-labeled water and indirect 
calorimetry methods. The double-labeled water technique measures carbon 
dioxide production and oxygen uptake in urine samples. The severity of PAD was 
measured by ABI. Additional tests for limb perfusion included transcutaneous 
heating power and calf transcutaneous oxygen measurements, which measure 
tissue perfusion of blood flow. The results did not find a significant correlation 
between ABI and EEPA (r = .236, p = .072) or transcutaneous oximetry (r = .239, 
p = .068), but found a significant negative correlation between EEPA and 
transcutaneous heating power (r = -.413, p = .002). This result demonstrated that 
subjects with higher levels of physical activity had better calf perfusion as 
measured by transcutaneous heating power. It is interesting that there was no 
significant correlation between ABI and EEPA, which suggest that other factors 
may influence physical activity in older adults with PAD.  
Gardner and Clancy (2006) evaluated the relationship between PAD 
disease severity and leisure time physical activity in a group of older adults with 
PAD. A group of 345 men and women with PAD (ABI < = 0.90), ranging in age 
from 45 to 85, were included in the study. Disease severity was measured by ABI 
and the subjects were divided into three categories of disease severity: mild PAD 
(0.70 - 0.89), moderate PAD (0.50 - 0.69), and severe PAD (< 0.50). Physical 
activity was measured by the Minnesota Leisure Time Physical Activity (LTPA) 
questionnaire, which determines the physical activity level of the person over the 
previous year. The LTPA also provided the duration and intensity of physical 
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activity. Results showed significant differences in LTPA between the three 
categories of disease severity (p = .030). There was also a significant difference 
between the groups for high intensity LTPA (p = .009) and moderate intensity 
LTPA (p = .016). There was no significant difference between the three groups of 
disease severity in low intensity LTPA. These results demonstrate that physical 
activity progressively declines as ABI declines and disease severity increases.  
McDermott and colleagues also evaluated the relationship between PAD 
disease severity and physical activity in a study of 460 subjects with PAD 
(McDermott, Greenland, Liu, Guralnik, Celic, & Criqui, et al., 2002). The group 
was 59.4% male with a mean age of 71.9 years old. The severity of PAD was 
measured by ABI and physical activity was measured by accelerometer over a 
seven-day period. Subjects were categorized into groups by disease severity/ABI 
and included mild PAD= 0.70 - 0.90, moderate PAD= 0.50 - 0.70, and severe 
PAD= less than 0.50. The results demonstrated that a lower ABI was associated 
with lower physical activity level as measured by accelerometer over seven days 
for mild PAD (β= -268, p<0.001) moderate PAD (β = -341, p < .001) and severe 
PAD (β = -523, p < .001). After adjustment for covariates, PAD disease severity 
was independently associated with level of physical activity.  
Usual Gait Speed. The value of utilizing usual gait speed (UGS) as an 
indicator of FP in older adults is well documented in the literature (Cesari, 
Kritchevsky, Penninx, Nicklas, Simonsick, & Newman, et al., 2005). Slower UGS 
is associated with subclinical cardiovascular disease (CVD) and even risk in 
older adults without known CVD (Hamer, Kivimaki, Lahiri, Yerramasu, Deanfield, 
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& Marmot, et al., 2010). Usual gait speed has been shown to be a significant 
predictor of disability in older adults and reported to be “nearly as good a 
predictor of disability as a full functional performance battery” (Guralnik, Ferrucci, 
Pieper, Leveille, Markides, & Ostir, et al., 2000).  
In the PAD population, the relationship between the severity of PAD and 
usual gait speed has been evaluated, albeit with conflicting results. Seven 
published studies from 1998-2008 were evaluated for this review. Six out of 
seven of the studies reviewed had extremely small sample sizes, all with fewer 
than 45 subjects in the PAD group (range from 9 - 40). Also, the majority of the 
subjects were male. Subjects in the comparison groups without PAD were 
likewise small, ranging from 10 - 26 subjects. Only one of the studies reported 
having done a power analysis, which indicated a minimum sample size of 200 
was required to achieve a power of 0.80; however, the final sample size for that 
study was n = 19 in the PAD group and n = 11 in the no PAD group (Scherer, 
Bainbridge, Hiatt, & Regensteiner, 1998).  
Despite being inadequately powered, these studies drew conclusions 
regarding the relationship between PAD severity and UGS. It is not surprising 
that the results are inconsistent. Scherer, et al. (1998) evaluated UGS and other 
parameters of gait in older adults with and without PAD (n = 19 and n = 11, 
respectively). The mean ABI for the PAD group was 0.54 (SD = 0.22). Although 
they found UGS to be significantly slower in the PAD group compared to the non 
PAD group, they did not find a correlation between PAD severity and any gait 
measure, including UGS.  
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Several other studies found UGS to be significantly slower in patients with 
PAD compared to those without PAD. Crowther, Spinks, Leicht, Quigley, and 
Golledge (2007) studied several different components of gait in a small group of 
patients with (n = 28) and without PAD (n = 25). The mean age of the subjects in 
the PAD group was 69.9 years old (SD = 1.5) compared to 66.2 years old  
(SD = 1.5) in the non PAD group. The mean ABI was 0.71 (SD = 0.04) for the 
right leg and 0.73 (SD = 0.05) for the left leg in the PAD group. In the non PAD 
group, the mean ABI for both legs was 1.16 (SD = 0.03). Fifty percent of the 
subjects in the PAD group were male and 40% of the subjects in the non PAD 
group were male. Similar to Chen, et al. (2008), Crowther, et al., found subjects 
with PAD to have a significantly slower UGS than those without PAD (1.08 m/sec 
vs. 1.30 m/sec, p < .001).  
McDermott, et al., (2001) evaluated alterations in gait in subjects with and 
without PAD. The sample size was n = 40 for the PAD group and n = 22 for the 
non PAD group. The mean age was 77 years old (SD = 7.7) in the PAD group 
and 71 years old (SD = 6.6) in the non PAD group. The mean ABI was 0.64  
(SD = 0.19) in the PAD group and 1.08 (SD = 0.08) in the non PAD group. The 
subjects in the PAD group were 50% male and in the no PAD group 59% were 
male. The researchers found UGS to be significantly slower in the subjects with 
PAD compared to those without PAD during both the first 100 feet and last 100 
feet of a six-minute walk test.  
Gardner, Forrester, and Smith (2001) evaluated gait characteristics in 
older adults with (n = 28) and without PAD (n = 15). The mean age of the sample 
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for both groups was 71 years old (SD = 1). Mean ABI in the PAD group was 0.65 
(SD = 0.03) compared to 1.09 (SD = 0.04) in the non PAD group. Ninety-three 
percent of subjects in both the PAD and no PAD groups were male. The results 
of the analysis showed that the subjects in the PAD group had 15% slower UGS 
than those in the non PAD group, which was a significant difference (p < .05).  
And finally, Kuo and Yu (2008) analyzed NHANES data from the 1999-
2002 cycles to evaluate the relationship of PAD severity and usual gait speed in 
older adults with PAD. This analysis included a subset of subjects over the age of 
60 with (n = 206) and without PAD (n = 1592). The sample was 50% male in the 
PAD group and 48% male in the no PAD group. This study found UGS to be 
significantly slower in the PAD group compared to the no PAD group (0.869 
m/sec vs. 0.994 m/sec, p < .001). However, the authors did not use survey 
sample weights in the analysis, which can result in biased estimates and 
standard errors (Johnson, Paulose-Ram, Ogden, et al., 2013).  
In summary, there are several studies in the literature that have evaluated the 
relationship between PAD severity and UGS. Most of the studies had small 
sample sizes and included primarily male participants. Overall, UGS was 
reduced in subjects with PAD.  
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Functional Capacity Indicators and Functional Performance 
Figure 1.5 Functional Capacity Indicators and Functional Performance 
Lower Extremity Strength. Lower extremity muscle strength is defined 
as the maximum force generated by an individual (Macaluso & de Vito, 2004). 
Muscle strength peaks between ages 20 - 30 and begins to decline at around 
age 50, with a subsequent yearly decline of 12-15% (Macaluso & de Vito, 2004; 
Samuel & Rowe, 2009). The ability to perform FP tasks is associated with muscle 
strength in older adults; reduced muscle strength results in a reduced ability to 
perform both upper and lower extremity FP tasks such as lifting and carrying 
shopping bags and getting up from a chair (Macaluso & de Vito, 2004). 
Declines in lower extremity strength have been documented in older 
adults with PAD. Histological studies have shown ischemic changes in skeletal 
muscle, including muscle fiber atrophy and denervation, which contribute to 
muscle weakness and loss of strength (Regensteiner, Wolfel, Brass, Carry, 
Ringel, & Hargarten, et al., 1993). Several studies that examined the impact of 
loss of muscle strength on functional performance indicators such as ADLs and 
physical activity in persons with PAD will be reviewed.  
PAD 
Severity 
FC 
FP 
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 Regensteiner, et al. (1993) characterized the effects of PAD on FC and 
FP. A sample of men with PAD (mean age 65 years, n = 26) and a sample of 
men without PAD (mean age 63 years, n = 6) were evaluated. Functional 
capacity indicators included muscle strength by dynamometer measures and calf 
muscle cross-sectional area. The functional performance outcome measure in 
this study was walking time on a treadmill. Histological analysis showed 
decreases in muscle fiber number and diameter in subjects with PAD, as well as 
muscle denervation, which was associated with decreased muscle strength in the 
limb. Gastrocnemius muscle strength was significantly decreased in PAD 
subjects compared with controls (30 lbs. vs. 53 lbs., p < .05). Muscle strength 
was weakly correlated with walking time on a treadmill (r = 0.41, p < .05). Calf 
muscle area was also significantly reduced in subjects with PAD compared to 
controls (94.5 cm2 vs. 99.7 cm2, p < .05). In summary, these factors were 
associated with FP in subjects with PAD. However, given that muscle strength 
was weakly correlated with walking time on a treadmill, additional FC indicators 
besides strength likely influence functional performance in subjects with PAD.  
A cross-sectional study by McDermott, Criqui, Greenland, Guralnik, and 
Liu, et al. (2004) assessed the relationships between PAD and lower extremity 
strength and functional performance. A total of 269 subjects with PAD (mean age 
73.2 years) and 245 subjects without PAD (mean age 69.5 years) were included 
in the study. Functional performance measures included the six-minute walk test, 
actual physical activity over a seven-day period as measured by accelerometer, 
and four-meter walking velocity.  
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Results showed significantly decreased lower extremity strength at all 
levels of testing in the PAD group compared to controls (hip extension, 61.4 
newton-meters vs. 71.6 newton-meters, p < .001; hip flexion, 54 newton-meters 
vs. 61.7 newton-meters, p < .001; knee flexion, 29.1 newton-meters vs. 35.4 
newton-meters, p <. 001). Six-minute walking distance was significantly lower in 
the PAD group compared to controls (1173 feet vs. 1402 feet, p < .001). The 
four-meter walking velocity was also significantly lower in the PAD group 
compared to controls (0.891 m/sec vs. 0.9330 m/sec, p < .05). Physical activity 
was lower in the PAD group than controls (864 activity units vs. 1040 activity 
units, p < .01). The severity of PAD, as indicated by ABI, was correlated with 
each FP outcome measure. However, after adjusting for leg strength, these 
correlations were decreased. Leg strength was a modest contributor in the 
relationship between the severity of PAD (decreased ABI) and lower extremity 
function as measured by four-meter walking velocity. Additionally, knee extensor 
strength was found to be independently associated level of physical activity. 
Lower extremity knee extensor strength was a significant predictor of six-minute 
walk distance (β = 3.78, p < .001), four-meter walking velocity (β = .002,  
p < .001), and seven-day physical activity level (β = 5.35, p < = .05).  
The above studies highlight strength as an important indicator of FC of 
persons with PAD, as well as the effect of strength on FP measures. In summary, 
some of the studies demonstrated a significant relationship between lower 
extremity strength and FP, but others did not.  
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Lower Extremity Sensory Impairment. Lower extremity nerve function 
can be impaired in persons with PAD. This can lead to a reduction in sensation 
and symptoms of numbness, pain, and tingling in the feet. These symptoms may 
influence functional capacity and functional performance.  
 Early histological and structural studies have demonstrated skeletal 
muscle and peripheral nerve changes in subjects with PAD (Farinon, Marbini, 
Gemignani, Govoni, Bragaglia, & Sianesi, et al., 1984). These impairments can 
contribute to decreased FC and FP in older adults with PAD.  
 England, Ferguson, Hiatt, and Regensteiner (1995) studied the effect of 
peripheral neuropathy on lower extremity function in a group of older adults 
(mean age 66 years) with PAD (n = 16). A group of seven patients (control) and a 
group of nine patients (exercise intervention group) were evaluated over a period 
of four months. The impact of PAD on muscle strength and nerve conduction was 
assessed using muscle strength testing, nerve conduction studies, and 
electromyographic studies (EMG). Evidence of muscle denervation was found on 
EMG, demonstrating motor axon disease in patients with PAD. Sensory nerves 
were also affected, as evidenced by declines in sensory action potentials. 
Additionally, nerve conduction studies showed defects in both motor and sensory 
nerves. Ischemic damage to nerves was suspected due to the nerve conduction 
pattern of disruption, which demonstrated primary axonal-loss and multifocal 
lesions. Lower extremity muscle strength declined in the control group and 
remained the same in the exercise group. Nerve conduction and EMG results 
were decreased in the exercise group as well as the control group. This study 
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demonstrates that both motor and sensory nerves are affected by lower extremity 
ischemia in PAD. Although the sample size was very small, the study adds to the 
evidence of ischemia-induced nerve dysfunction based on EMG and nerve 
conduction studies.  
Muscle and nerve impairments resulting from PAD-associated ischemia 
and lower extremity functioning were examined in the InCHIANTI Study 
(McDermott, Guralnik, Albay, Bandinelli, Miniati, & Ferrucci, 2004). The 
InCHIANTI Study is a cross-sectional study (n = 109) that evaluated men and 
women aged 60 and over that resided in surrounding communities of Florence, 
Italy. The purpose of the study was to determine whether PAD was associated 
with muscle and nerve impairment as evidenced by nerve conduction studies, 
muscle cross-sectional area, and lower extremity muscle power. Functional 
performance outcome measures included a 400-meter walk and fast four-meter 
walking speed. There were significant differences in all functional performance 
measures between the PAD and no-PAD group fast four-meter walking speed 
(1.28 m/s vs. 1.42 m/s, p < .001) and 400-meter walk (392.28 meters vs. 336.41 
meters, p < .001). Muscle and nerve variables were also significantly different 
between the PAD and no-PAD group as seen in nerve conduction velocity (43.04 
m/s vs. 44.16 m/s, p < .01) and muscle power (83.69 watts vs. 103.51 watts,   
p < .001). Muscle cross sectional area was not significantly different between the 
two groups. The study also evaluated the relationship between PAD severity and 
the functional performance measures above with and without adjustment for 
nerve conduction velocity. These results demonstrated that PAD severity was 
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significantly associated with functional performance measures such as fast 
walking velocity. The relationship between PAD severity and functional 
performance measures did not significantly change after adjustment (in separate 
analyses) for nerve conduction velocity or muscle cross-sectional area. This 
indicates that nerve conduction velocity and muscle cross-sectional area do not 
completely explain the relationship between PAD and functional performance. 
The relationship between PAD severity and functional performance was slightly 
attenuated when adjusting for muscle power, suggesting that muscle power may 
be a mediator in the relationship between PAD and functional performance.  
Lower extremity nerve function was studied in a group of men and women 
with and without PAD (n = 770) to evaluate the association between PAD and 
lower extremity nerve function (McDermott, Sufit, Nishida, Guralnik, Ferrucci, & 
Tian, et al., 2006).  Because diabetes is associated with peripheral neuropathy, 
the study controlled for diabetes in patients with and without PAD. Studies of 
nerve function included evaluation of motor and sensory nerves by nerve 
conduction velocity in the peroneal (motor) and sural (sensory) nerves. Results 
demonstrated that subjects with severe PAD (without diabetes) had worse 
peroneal nerve conduction velocity that those without PAD (42.6 m/s vs.  
44.8 m/s, p < .01). Subjects with mild PAD (without diabetes) also had worse 
peroneal nerve conduction velocity than those without PAD (42.6 m/s vs. 
44.1 m/s, p < .01). Subjects with diabetes and PAD had worse peroneal nerve 
conduction velocity (40.8 m/s vs. 43.5 m/s, p < .05) and lower sural nerve 
amplitude (3.1 µV vs. 4.8 µV, p < .05) than those without PAD. In summary, 
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subjects with PAD were reported to have worse nerve function in all areas than 
those without PAD. In PAD subjects with diabetes, all measures of nerve function 
were worse than in those with PAD and no diabetes. After controlling for 
diabetes, PAD was still associated with reduced peroneal nerve function. 
However, there was not an association between sural nerve function and PAD 
after controlling for diabetes. The study suggests that motor nerve function is 
directly affected by PAD but the impact of PAD on sensory nerve impairment 
remains unclear.  
Gaps in Scientific Literature 
The Indirect Effect of Functional Capacity. A review of the current 
scientific literature demonstrates a lack of evidence for mediation of the 
relationship between PAD severity and several individual indicators of FC. 
Several of the studies reviewed suggested mediating variables, in particular, the 
FC indicator lower extremity strength. There is some evidence to support 
associations between PAD and reduced lower extremity strength (McDermott, 
Liu, Lu, Guralnik, & Criqui, 2012) as well as lower extremity strength as a 
mediator between PAD severity and indicators of FP. However, the statistical 
methods used to evaluate strength as a mediator are unclear, incomplete, or the 
results are conflicting.  
For example, Herman, Liu, Lu, Guralnik, Ferrucci and Criqui, et al. (2009), 
studied changes in lower extremity strength in older adults with PAD with a five-
year follow-up. This study included a sample of 374 subjects, both men (n = 222) 
and women (n = 152) aged 55 and over with PAD. Lower extremity strength was 
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measured using isometric testing of both hip and knee flexion and extension. The 
main outcome measure was change in six-minute walking distance, measured 
annually for a mean follow-up of five years. Subjects had testing done upon entry 
to the study to establish baseline values and were retested annually. The primary 
aim of the study was to determine whether there was an association between 
lower extremity strength and “functional decline” in men and women with PAD. A 
secondary aim was to determine whether strength “was in the causal pathway” of 
association between PAD and decline in FP.  
The authors found that lower extremity strength measures at baseline 
were associated with average “functional decline” in women, but not men. The 
reasons for this finding were unexplained, and the data for the main outcome 
measure for both men and women were not included in the paper. Some factors 
that may have contributed to this lack of finding include lack of power due to 
small sample size for between-group analysis, as participants were grouped by 
strength tertiles and had 40 - 50 subjects. Also, the authors reported missing 
data for the follow-up visits, but the amount or patterns of missing data were not 
available. Missing data was handled using multiple imputation, but the process 
for imputing data was not reported. Certainly, any and all of these factors can 
influence analysis and final results. It would be interesting to repeat this study 
using growth models and/or survival modeling (Muthen & Muthen, 2013).  
Lower Extremity Sensory Impairment. The research studies included in 
this review have highlighted the role of lower extremity nerve impairment in 
functional performance in subjects with PAD. These studies provided evidence 
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for the effect of nerve impairment on functional performance in persons with 
PAD. However, one of the studies did not show that nerve impairment affects 
lower extremity function (McDermott, Guralnik, Albay, Bandinelli, Miniati, & 
Ferrucci, 2004), indicating that further study is required to delineate this issue. 
Furthermore, most of the studies focused on motor nerve dysfunction, and 
information on the role of sensory nerve impairment is limited. One of the studies 
did suggest that sensory nerve function is impaired in persons with PAD. Our 
study provides an opportunity to further clarify the role of sensory impairment in 
PAD and its influence on lower extremity function. In addition, the influence of 
sensory impairment on functional capacity and functional performance is not 
known. This gap in knowledge can be addressed in this study. 
Multivariate Analysis. Research to date has provided strong evidence of 
bivariate relationships between PAD severity and indicators of FC and FP. 
However, multivariate analysis is necessary to analyze the factors that impact FP 
in older adults with PAD, simultaneously. This gap in the literature is also 
addressed by this study.  
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CHAPTER III: 
METHODS 
Research Design 
The specific aims were accomplished by a secondary data analysis using 
a publicly available data set, the continuous National Health and Nutrition 
Examination Survey (NHANES), available from the data archives of the Centers 
for Disease Control (http://www.cdc.gov/nchs/nhanes.htm). The NHANES data 
sets are available in 2-year cycles and the sample for this study will be drawn 
from the 1999 - 2000 and 2001 - 2002 cycles. The 2003 - 2004 cycles were not 
included because several of the selected variables were not available for this 
cycle. The NHANES survey is a complex probability sample of non-
institutionalized civilians of the United States population. It includes three testing 
components, the household interview, physical exam, and blood testing.  The 
physical exam and blood testing were completed at the NHANES mobile 
examination center and the household interview was conducted at the 
participant’s home. Demographic, socioeconomic, dietary, and health-related 
information was obtained during the household interview. The physical exam 
included medical exams, dental exams, and physiological testing (such as 
cardiac, pulmonary, and functional testing).  A comprehensive variety of blood 
tests were also completed.  
Setting and Sample 
Participants for the NHANES two-year cycles were selected using 
information from the US Census Bureau. The sampling procedure consisted of 
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four stages. Stage 1 was the selection of the primary sampling units, which were 
single counties across the US. Stage 2 was the division of the primary sampling 
units into segments of city blocks. Stage 3 was the random selection of 
households from the city blocks. Stage 4 was the random selection of individuals 
within the households. The average number of persons selected from each 
household was 1.6. (Johnson, Paulose-Ram, Ogden, et al., 2013). Sample 
weights were used in order to obtain an unbiased national estimate. Use of the 
sample weights is required for analysis of the 1999 - 2002 survey cycles in order 
to reflect the unequal probability of sample selection (Johnson, et al., 2013). The 
NHANES survey intentionally over-sampled African-American, Hispanic, low-
income White Americans, and adults over the age of 60.  
The sample for this analysis was drawn from the 1999 - 2000 and        
2001 - 2002 NHANES survey cycles. The total survey sample was N = 21,004. 
The subsample of interest consisted of all surveyed persons, men and women 
aged 50 and older (n = 3695). The subsample was divided into two groups for the 
analysis, those subjects with an ankle-brachial index (ABI) of < = 0.90 (PAD 
group, n = 378) and those subjects with an ABI of > = 0.91 (no PAD group,  
n = 3317). 
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TOTAL COMBINED SAMPLE 
1999 - 2002 NHANES SURVEY CYCLES 
N = 21,004 
TOTAL SUBSAMPLE AGE > = 50 YEARS OLD 
n = 3695 
NO PAD GROUP  PAD GROUP 
            n = 3317 n = 378 
Figure 1.6 Sample Size Determination 
Measures 
This study is a secondary analysis of data derived from the NHANES 
publicly available data from cycles 1999 - 2002. The measures for the variables 
were limited to what were used by the NHANES investigators. Reliability and 
validity is reported when available.  
Descriptive Measures 
Demographic characteristics included age, gender, race, income, marital 
status, and highest level of education. Categories of race included non-Hispanic 
white, non-Hispanic black, Mexican-American, other Hispanic, and other 
racial/multi-racial. Marital status categories included never married, married, 
divorced, widowed, separated, and living with partner. Education categories 
included less than 9th grade, 9 - 11th grade, high school graduate/GED, some 
college/Associates degree, and college graduate and above. There were nine 
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categories of household income, ranging from zero to greater than 75,000 per 
year. Age-adjusted frequencies for medical conditions including hypertension, 
diabetes, high cholesterol, coronary artery disease, congestive heart failure, 
myocardial infarction, stroke, arthritis, and cancer were compared between 
groups.  
Functional Capacity Observed Indicators 
Lower Extremity Strength 
Knee extensor strength was measured using the Kinetic-Communicator 
(Kin-Com) dynamometer (Chattecx Corp., Chattanooga, TN) on all subjects aged 
50 and over. The Kin-Com dynamometer is a computer-controlled device used to 
evaluate dynamic strength characteristics of various joints in the body.  The Kin-
Com measures muscle force by providing resistance during isokinetic movement 
and isometric muscle contractions (Mayhew, Rothstein, Finucane & Lamb, 1994). 
Muscle strength examinations were conducted at the mobile examination 
center. Knee extensor strength was measured in peak torque (newton-meters) of 
the quadriceps muscle at the speed of 60 degrees per second. A total of six 
muscle strength trials were obtained which included three warm-up 
measurements followed by three actual test measurements. The average of the 
three actual test measurements was used as the variable in this study. In order 
for the strength variable to be on a similar scale as the other variables in the 
study, strength was converted from newton-meters to kilograms. This was done 
only for input to Mplus for the confirmatory factor analysis and structural equation 
modeling analyses.  
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The reliability and test-retest reliability of the Kin-Com dynamometer has 
been evaluated previously in a study using controlled laboratory conditions 
without human subjects (Mayhew, Rothstein, Finucane & Lamb, 1994). 
Measurements of force, angle, and velocity of the Kin-Com device were 
evaluated on two different days. Intraclass correlation coefficients for between-
day measurements of force, angle and velocity were above 0.99.  
Lower Extremity Sensory Impairment 
Lower extremity sensory impairment was evaluated by the Semmes-
Weinstein Monofilament (SWM) test in subjects over 40 years of age in the 
mobile examination center. The SWM is performed to detect loss of sensation in 
the feet (Dros, Wewerinke, Bindels & van Weert, 2009). The SWM test was 
performed using a 5.07 monofilament with a ten-gram filament force. Slight 
pressure was applied in non-sequential order with the monofilament to the 
plantar-first metatarsal head, the plantar fifth metatarsal head, and the plantar 
hallux. The number of correct and incorrect responses is counted and recorded. 
A site was considered to be sensate if the subject responded correctly on the first 
attempt or had two correct responses out of three. A site was considered to be 
insensate if the subject responded incorrectly twice or if the subject responded 
incorrectly one time and another time was unable to determine a response either 
way. The total number of insensate areas was recorded for each foot (0 - 3). The 
right and left total number of insensate areas was summed to create one 
continuous score (0 - 6).  
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Monofilament testing is a commonly used screening measure and it has 
not been shown to be accurate for the diagnosis of peripheral neuropathy (Dros, 
Wewerinke, Bindels, & van Weert, 2009). However, a recent systematic review 
found sensitivity to range between 41 - 93% and specificity to range between 68 -
100% (Dros, Wewerinke, Bindels & van Weert, 2009). While not adequate for the 
diagnosis of peripheral neuropathy, the American Diabetes Association (ADA) 
does recommend the use of a 5.07/10 g monofilament as part of the 
comprehensive foot examination and risk assessment in diabetics. The ADA also 
recommends the monofilament test to screen for sensory loss in the feet 
(Boulton, Armstrong, Albert, Frykberg, Hellman, & Kirkman, et al., 2008). 
Predictive validity has been demonstrated using the 5.07/10 g monofilament test; 
an abnormal test has been reported to be a predictor for the development of foot 
ulceration and amputation (Godhes & Rith-Najarian, 1995; Rith-Najarian, 
Stolusky, & Godhes, 1992).  
In the absence of a diagnosis of peripheral neuropathy by the accepted 
reference standard (nerve conduction study), the ADA recommends a clinical 
examination plus more than one test for diagnosis (Boulton, et al., 2008). Tests 
include vibration sensation with a tuning fork, pressure sensation with a 
monofilament, ankle reflexes and pinprick test (Boulton, 2008). However, the 
monofilament test continues to be recommended as a screening tool to assess 
the foot for loss of sensation.  
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Calf Circumference 
The measure of maximum calf circumference was included in the 
anthropometric section of the physical exam. The anthropometric examination 
included several different body measurements. The exam was completed in the 
MEC by a trained examiner and recorder. A measuring tape was used to 
determine the maximum calf circumference of the right leg in centimeters.  
Functional Performance Observed Indicators 
Physical Function Questionnaire 
Thirteen items were selected from the NHANES Physical Function 
Questionnaire (PFQ) (Appendix A) which was conducted as part of the 
household interview. The NHANES PFQ is a 19 - item scale that measures ADLs 
such as dressing and eating, leisure activities such as reading and watching 
television, and ability to perform on physical activities such as walking, stooping, 
and lifting. Items were scored as 1 = no difficulty, 2 = some difficulty, 3 = much 
difficulty, 4 = unable to do, and 9 = don’t know.  
Individual items for this study were selected based on relevancy to the 
research questions and non-relevant items were excluded. Items involving the 
upper extremity function and managing finances were removed. Thirteen items 
were chosen and a total score variable was created with a possible score range 
of 13 - 52. A high total PFQ score represents worse physical function. The 
reliability for the items used in the PFQ scale for this study was 0.91.  
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Average Level of Daily Physical Activity 
Self-reported average level of daily physical activity was measured using a 
single question from the NHANES Physical Activity Questionnaire (PAQ). The 
participant was asked to select the response that most accurately reflected the 
level of average daily physical activity. The responses were coded as 1 = sits 
most of the day and does not walk very much, 2 = stand or walks a lot during the 
day but does not have to lift or carry things very often, 3 = lifts light loads or 
climbs stairs or hills often, and 4 = does heavy work or carries heavy loads. This 
variable was considered continuous with a higher score reflecting higher level of 
self-reported average daily physical activity. Participants could also answer 7 = 
refused and 9 = don’t know. These two items were recoded as missing (-999) for 
the purpose of transferring into Mplus for analysis. The full PAQ used in the 
NHANES study was recently validated against accelerometer data collected in 
the 2003 - 2004 cycle in adults over the age of 18 who had been advised to 
increase physical activity for cholesterol control (Fan, Ham, Muppidi, & Mokdad, 
2009).  
Usual Gait Speed 
Usual gait speed has been shown to be a predictor of physical function in 
older adults. In this study, usual gait speed was determined by a timed 20 - foot 
walk. This test was completed in the MEC as an adjunct to the muscular strength 
exam. A walking test track was created in the MEC and the start and end points 
were marked with tape. The participant was asked to walk the length of the test 
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track at their usual, comfortable walking speed. The walk was timed with a 
handheld stopwatch and measured in seconds. 
Observed Endogenous Variable 
PAD Severity 
Peripheral arterial disease severity was determined by the value of the 
ankle-brachial index (ABI). All subjects included in the study had an ABI 
completed in the MEC portion of the NHANES health survey. The ABI is a non-
invasive and efficient test commonly used to diagnose PAD. The ABI is a 
calculation of the highest systolic ankle pressure (posterior tibial artery and/or the 
dorsalis pedis artery) divided by the highest systolic brachial pressure using a 
Doppler and blood pressure cuffs. A normal ABI is between 1.0-1.15 and PAD is 
suspected when the ABI is lower than 0.90. The sensitivity and specificity for 
diagnosing PAD in an ABI less than 0.90 is 95% and 99%, respectively 
(Bernstein & Fronek, 1982). The ABI has also been shown to be reproducible 
and reliable, with a reported mean intraobserver and interobserver error of 8-9% 
(Holland-Letz, Endres, Biedermann, Mahn, Kunert, & Groh, et al., 2007).  
For the purposes of this study, the lowest ABI recorded between the right 
and left legs was selected for use in the analysis. A new variable was created to 
represent this value. This variable was used to place subjects into two groups, 
with and without PAD. Subjects were selected for the PAD group if they had an 
ABI of less than or equal to 0.90. Subjects were selected for the NO PAD group if 
they had an ABI of greater than or equal to 0.91. A grouping variable was also 
created.  
38 
Study Procedures 
Data Acquisition and Preparation 
The 1999 - 2000 and 2001 - 2002 demographics, questionnaire, 
examination and laboratory data files were downloaded from the NHANES 
website (Johnson, 2013) in the form of SAS transport files. Files were appended 
to create one data set representing the  
1999 - 2002 survey years.  Variables of interest were merged from the individual 
data files to the 4-year dataset by the subject identification number. Once a 
complete 4-year dataset was created, key variables of interest were analyzed 
and recoded if indicated. To account for the complex survey design, the entire  
4-year sample (N = 21,004) was retained and a subpopulation variable was 
created to identify all subjects > = 50 years of age. Complex sample weights for 
the interview and examination were retained. The variables representing cluster 
and stratum were provided by NHANES for the survey years 1999 - 2002, so no 
additional analysis was required to calculate these weights.  
Data Management 
All data management subsequent to the download, appending, and 
merging of datasets was completed in SPSS (Version 21.0 Complex Samples, 
IBM, 2013). A complex sample plan file was created in the SPSS complex 
samples package. This plan file included the cluster, strata, and subject interview 
and examination sampling weights. This also included creation of a 
subpopulation variable to identify the selected sample population of all adults  
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> = 50 years of age who had ABI testing done. Dummy variables were created 
for gender and diabetes. A grouping variable was then created for presence or 
absence of PAD. Subjects were placed into a ‘no PAD’ or ‘PAD’ group depending 
on the value of the ABI. Missing data were re-coded to -999. A complete dataset 
was required for input into Mplus, therefore, all character missing (blanks), 
numeric missing (period), ‘refused’, ‘don’t know’ entries were re-coded as -999 
for missing. Descriptive statistics were calculated in SPSS.  Multigroup 
confirmatory factor analysis and structural equation modeling were run in Mplus 
7.11 (Muthen & Muthen, 2013). 
Power Analysis-Degrees of Freedom 
Degrees of freedom were calculated in order to perform the power 
analysis. The number of model parameters was determined by the sum of the 
observed variables, estimated regression coefficients, variances, and 
covariances. The full SEM model had 9 observed variables, 11 regression 
coefficients, 3 variances and 5 covariances. The total number of model 
parameters was 27. Degrees of freedom were calculated using the equation 
below where n = the number of observed variables. Total degrees of freedom for 
the full SEM model was calculated as 18 (Appendix A). 
Power Analysis-Sample Size 
Power analysis was performed in order to determine the estimated power 
for the intended SEM analysis in this study. The first step in the power calculation 
was to calculate the design effect (DEFF) and effective sample size (ESS) for 
each group. The DEFF is the estimated increase in variance due to the complex 
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survey design. Effective sample size represents the equivalent sample size for 
each group had the sample been drawn from a simple random sample (West, 
Berglund, & Heeringa, 2008). The ESS was subsequently used in the final power 
calculation.  
Effective sample size was obtained by dividing the actual sample size by 
the average DEFF for each group. To calculate the DEFF for each group, 
general linear model was selected from the complex samples package in SPSS. 
Per NHANES analytic guidelines, the MEC weight is recommended if subjects 
had both the interview and exam completed (Johnson, 2013). Next, a linear 
regression was run for each path in the hypothesized model and path-specific 
design effects were obtained for each group. Design effects were then entered 
into an excel spreadsheet and an average DEFF for each group was calculated. 
The average design effect for the NO PAD group was 1.299 and 1.382 for 
the PAD group. The total number of actual subjects were 3317 and 378 for the 
no PAD and PAD groups, respectively. 
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The ESS were calculated as n/DEFF: 
Actual 
Sample 
Size 
Average 
DEFF 
ESS 
NO PAD 3317 1.299 2553 
PAD  378 1.382   273 
Table 3.1 Estimated Sample Size 
Next, a power analysis was conducted to determine if the ESS of each 
group was adequate for a desired minimum power of 0.80. A web-based utility 
program was used to generate syntax for the statistical program R (Preacher & 
Coffman, 2006). To generate the R syntax, the desired alpha level, the model 
degrees of freedom, desired null root mean squared error (RMSEA), and 
alternative RMSEA were entered. Once the R syntax for calculating power was 
generated, it was submitted to Rweb, a web-based R interface, which ran the R 
syntax and produced the desired power analysis (Preacher & Coffman, 2006). 
For an alpha level of .05, df = 18, desired power of .80, null RMSEA .05 and 
alternative RMSEA of .10, the estimated minimum sample size was calculated as 
n = 207. Therefore it was concluded that each separate group included in this 
study, had an adequate ESS to detect a power of .80 in model tests of close and 
not-close fit.  
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Data Analysis 
Missing data 
To examine the amount of missing data, a missing value analysis was 
performed in SPSS. The 6 observed latent variable indicators (lower extremity 
strength, lower extremity sensory impairment, calf circumference, ADL, UGS, 
PA) and 4 observed exogenous variables (ABI, age, gender, diabetes) were 
included.  
In the NO PAD group (n = 3317), seven out of ten variables had less than 
5% missing values. The remaining three variables, lower extremity strength, calf 
circumference, and PFQ items, had 23.8%, 24%, and 27% missing values, 
respectively. In the PAD group (n = 378), eight out of ten variables had less than 
10% missing values. The remaining two variables, lower extremity strength and 
calf circumference, had 36% and 32% missing values, respectively. Table 3.1 
summarizes the reasons for missing data on the strength variable for the PAD 
group and table 3.2 for the no PAD group. The reasons for missing data are 
listed by general and specific exclusion criteria for participation in the exam. In 
both groups, the calf circumference variable missing data were recorded as 
“could not obtain” by NHANES. Examination protocols for body measures stated 
that inability to obtain measures was due to inability or refusal to remove clothing, 
bone deformities, body size or measures that exceeded the maximum possible 
measurement due to instrument limitations. No subjects in this subsample had 
right or left lower extremity amputations.  
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Little’s Missing Completely at Random (MCAR) test (Little, 1988) was 
performed to determine if the data was MCAR. This output was obtained by 
checking the expectation-minimization box in the missing value analysis in 
SPSS. The chi-square statistic and significance level were included in the output. 
For both the PAD and NO PAD groups, Little’s MCAR test was significant, which 
indicated that the data were not MCAR (Little, 1988). Therefore, the missing data 
were determined to be missing at random.  
Missing Data Handling 
The options considered for handling the MAR data included multiple 
imputation or full-information maximum likelihood (FIML) estimation.  
Full-information maximum likelihood estimation uses all available data for 
estimation, while multiple imputation replaces missing values. Multiple imputation 
was attempted using Mplus. The imputation procedure was successful, and five 
separate, imputed datasets were created which contained the model and 
auxiliary variables (SEQN, age, gender, survey weights, etc.). Running the 
imputed datasets was also attempted using Mplus (TYPE = IMPUTATION), but 
analysis was abandoned after inability to combine the TYPE = IMPUTATION and 
TYPE = COMPLEX with multigroup analysis.  
Simulation studies have shown that in data MAR, FIML produces efficient, 
unbiased parameter estimates and standard errors (Enders & Bandalos, 2009; 
Larsen, 2011). It has been shown to perform superiorly compared to alternative 
methods such as pairwise deletion (Enders & Bandalos, 2009) and multiple 
imputation (Larsen, 2011). Full-information maximum likelihood with observed 
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information is the default in Mplus for TYPE = COMPLEX using the MLR 
estimator. Therefore, this was the option used to handle the MAR data in this 
analysis.  
Evaluation of Assumptions 
The Maximum Likelihood (ML) estimator is commonly used in SEM 
analyses and often the default for many statistical programs including Mplus 
(Muthén & Muthén, 2013). Certain assumptions are present with the use of the 
ML estimator (Hoyle, 2012). These include the assumption of multivariate 
normality, independence of observations, and no missing values. It is also 
assumed that the endogenous variables have no measurement error.  
Multivariate Normality 
 Multivariate normality is an assumption of the data in SEM analysis 
(Hoyle, 2012). To test the six observed variables (strength, calf circumference, 
sensory impairment, usual gait speed, physical activity, PFQ) for multivariate 
normality, the multivariate normality test command was utilized in Stata13 (Stata, 
2013). The results included the Doornik-Hansen Omnibus test for multivariate 
normality (Doornik & Hansen, 2008), the Henze-Zirkler test (Henze & Zirkler, 
1990), and Mardia’s tests for skewness and kurtosis (Mardia, 1970). The results 
showed that p-values were significant at p < .000 for all tests, therefore indicating 
that multivariate normality was not present in the observed variables 
Solution for Violation of Normality Assumption 
In Mplus, the default estimator for CFA and SEM is Maximum Likelihood 
(ML), which assumes multivariate normality (Muthén & Muthén, 2013). Ignoring 
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the normality assumption would lead to inaccurate model fit statistics and biased 
standard errors. Therefore, an alternative solution for handling the continuous, 
non-normal data with missing values was selected.  
The decision was made not to transform the data prior to input and 
analysis in Mplus. Instead, the Maximum Likelihood Robust (MLR) estimator was 
selected. The MLR estimator is the default in Mplus analysis for complex survey 
sample (TYPE = COMPLEX). It has been shown to provide unbiased estimates 
and standard errors in a sample with missing values, and less biased estimates 
and standard errors in samples that have both missing values and non-normal 
data distributions (Yuan, Wallentin, & Bentler, 2012). Given the presence of non-
normally distributed data with missing values, it was the estimator of choice for 
this study.  
Model Specification 
Model Identification 
The hypothesized measurement model was evaluated for identification in 
several ways. First, the “three indicator” rule of thumb was applied. This rule 
states that in order for a latent variable model to be identified, latent variables 
must have a minimum of three indicators. The hypothesized model in this study 
has a minimum of three indicators per latent variable. Second, in order for a 
model to be identified, the degrees of freedom must be greater than or equal to 
zero. The total degrees of freedom for the hypothesized model were 18. Third, 
the latent variables must be assigned a scale. In the hypothesized model, this 
was achieved by fixing the path coefficient of one latent variable indicator 
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(reference variable) to 1.0. The latent variable scale then is based on the shared 
variance of the reference variable. And lastly, the model was recursive. This was 
evident by unidirectional paths without feedback loops. All criteria for 
identification were met and the hypothesized model was considered identified.  
Disturbances 
The disturbances, or the residuals of the exogenous (observed) variables, 
were allowed to covary in this model. Theoretical foundation supports a 
covariance between the disturbances of the latent variable indicators. The latent 
variable disturbances were also allowed to covary in the model.  
Modification Indices 
Modification indices with a value of 10 or greater are reported as the 
default in Mplus (Muthén & Muthén, 2013). Modification indices were requested 
in the output command of the input syntax (modindices (all)). Modification indices 
were considered if adding the parameter made conceptual sense, and if there 
would be a substantial change in the chi-square by adding it. 
Model Fit Indices 
The model fit indices that were selected for both the measurement and 
structural models included the root mean squared error of approximation 
(RMSEA), the comparative fit index (CFI), and the standardized root mean 
square residual (SRMR). The RMSEA is a measure of model badness-of-fit 
(Hoyle, 2012) with the lower bound value of zero indicating improved model fit. 
The RMSEA value between 0 and 0.05 is commonly accepted as the model 
having a “close fit” (Hoyle, 2012). Some references report the RMSEA to be as 
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high as 0.08 for an “acceptable” fit, with any value greater than 0.08 to be 
considered “unacceptable” model fit. The RMSEA confidence intervals (CI) 
describe the precision of the estimate and a narrow CI is desired. The CFI is 
considered a measure of model “goodness of fit”, with the possible range 
between zero and one. The higher the CFI, the better the model fit with the cutoff 
criterion of an acceptable CFI of > 0.90, with a preferred CFI of > 0.95 (Bentler, 
1990). The SRMR is a measure of model “badness-of-fit” with a minimum value 
above zero, with the cutoff criterion of < 0.08. Both the RMSEA and SRMR are 
sensitive to small sample sizes, while the CFI is not. These three model fit 
indices reflect the current “gold standard” in model fit index reporting (Hoyle, 
2012). 
Model Testing 
Multigroup Confirmatory Factor Analysis 
To assess the validity of the measurement model (Figure 3.2), 
confirmatory factor analysis (CFA) was performed to test for measurement 
invariance between the two groups. This analysis was completed before 
proceeding with analysis of the hypothesized full structural equation model.  
First, pre-analysis decisions will be discussed followed by the specific CFA steps. 
Mplus Version 7.11 was the software choice for all CFA and SEM 
analyses (Muthén & Muthén, 2013). The dataset prepared in SPSS was saved 
as a raw data file without variable names in the form of a comma separated file 
(.csv). The order of the variable names was recorded for the CFA input file code 
created to run the analysis. The data file was specified in Mplus along with the 
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names of the variables in order they appear in the corresponding dataset (.csv 
file). The cluster, strata, and sample weights were also included. The type of the 
analysis was TYPE = COMPLEX, and Maximum Likelihood Robust (MLR) 
estimator was selected.  
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Figure 3.2 Measurement Model  
FC= Functional Capacity, FP= Functional Performance, SI= Sensory Impairment, 
STR= LE Strength, CC= Calf circumference, PA= Physical activity, PF= Physical 
Function, UGS= Usual Gait Speed, d1, d2= Latent variable errors, e1-e6=  Latent 
variable indicator errors 
STR 
SI 
CC 
PA 
PF 
UGS 
FC 
FP 
d1 
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e2 
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d2 
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Measurement Model Invariance 
To test for measurement invariance between the two groups, a series of 
stepwise models were tested, with the level of measurement invariance 
increasing with each step (Muthén & Muthén, 2013). First, the measurement 
model fit was evaluated in each group separately. Then, parameter constraints 
were imposed on the model in a stepwise fashion to test for configural 
invariance, metric invariance, and scalar invariance. Lastly, the groups were 
tested for invariance of factor variances, error variances, and latent variable 
means. Factor score determinacy was requested for both groups to determine 
the quality of the factor scores.  
Configural invariance is determined by testing for equality of the 
measurement model between the two groups. To test for configural invariance, 
the measurement model fit was estimated in each group separately, then 
between the groups. This was achieved by allowing all model parameters to be 
freely estimated while fixing both factor means to zero. Metric invariance was 
determined by testing for equality of the factor loadings between groups. To test 
for metric invariance, all factor loadings were constrained to equality in both 
groups. Scalar invariance tested for invariance in the intercepts between groups. 
To test for scalar invariance, the intercepts were held to equality in both groups. 
To test for strict factorial invariance, equality constraints were placed on the 
factor variances in both groups. Strict factorial invariance allows factor means 
and covariances to be freely estimated. 
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Chi-square Difference Testing 
In order to compare the model B (metric) with model A (configural) and 
model C (scalar) with model B and model A, the Satorra-Bentler scaled chi-
square difference test for nested models was performed (Satorra & Bentler, 
1999). This is different than the Satorra-Bentler scaled chi-square test (Satorra & 
Bentler, 1994), which cannot be used for nested models because the chi-square 
difference would not lead to a chi-square difference statistic (Satorra, 1999). 
Instead, in the case of nested models, a chi-square difference test for the 
Satorra-Bentler scaled chi-square was calculated manually using a 
recommended formula (Muthen & Muthen, 2013; Satorra-Bentler, 1999): 
Multigroup Analysis: Latent Variable Means and Intercepts 
Parallel Slopes 
To determine between-group differences in latent variable intercepts while 
controlling for the exogenous variables, a parallel slopes model was tested. The 
factor loadings of age, gender, diabetes, and ABI were constrained to equality for 
both groups. Since the no PAD group had the latent variable intercepts set to 
zero, the between-group difference for latent variable intercept was estimated. 
Non-Parallel Slopes 
To determine between-group differences in latent variable means with the 
effect of different values of the exogenous variables on the latent variable, a non-
parallel slopes model was tested. Equality constraints were released and the 
effect of age, gender, and ABI on functional capacity and functional performance 
was allowed to vary. 
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The equality constraint on gender was released for both functional 
capacity and functional performance. Both ABI and age remained constrained to 
equality between groups. Gender was coded as a dummy variable with  
0 = female and 1 = male. The model was estimated and the coefficients were 
entered into the non-parallel slopes regression model:  
regression model Y = b0 + b1 D1 + b2 X1 + b3 (D1 * X1) 
Testing for Indirect Effects in Latent Variable Model 
After demonstrating configural, metric, and scalar invariance between the 
groups, the full structural equation model was tested (Figure 3.3). The path of 
interest was the causal path from the exposure variable PAD severity to 
functional performance. To test the hypothesis that the functional capacity 
mediates the relationship between the exposure variable ABI and functional 
performance, estimates were first obtained from mediation analysis using the 
MODEL INDIRECT command in Mplus 7.2 (Muthen & Muthen, 2014). After 
estimates and standard errors were calculated, they were entered into the Monte 
Carlo (MC) online utility for calculating the 95% CI (Selig & Preacher, 2008). The 
MC 95% CI was considered to be significant if the CI did not contain the value of 
zero (MacKinnon, Lockwood, & Williams, 2004).  
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Metric of Latent Variables 
The reference-group method was the default in Mplus 7.11 as the method 
to identify the metric of the latent variables. This default assigned the first group 
(in this study the no PAD group) as the reference group and the latent variable 
means were set to zero and the latent variable variance fixed to one. The 
loadings and intercepts of the factor indicators were set to equality across the 
two groups. This allowed for the difference in the latent variable means between 
groups to be estimated. 
Differences in Latent Variable Means  
In order to compare the difference in latent variable means between the 
no PAD and PAD groups the ALIGNMENT METHOD was used (Muthen & 
54 
Muthen, 2013). The Mplus default sets the latent variable means to zero in the 
reference group (the no PAD group) and are free to be estimated in the PAD 
group. This allows the difference in the latent variable means to be compared 
across groups.  
Equivalent Models 
The possibility of equivalent models was investigated as part of this 
dissertation. Equivalent models differ in the relationships between model 
variables that result in identical predicted covariance matrices and fit indices as 
the proposed model (Hoyle, 2012). Hershberger (2006) has proposed a method 
called “the replacement rule” to evaluate for equivalent models. To implement the 
replacement rule, the full structural model is separated into blocks called 
preceding blocks, focal blocks, and succeeding blocks. The full structural model 
is annotated according to the replacement rule in Figure 3.4 below. The possible 
equivalent model tested for this study is shown in Figure 3.5. Using the 
replacement rule, the direction of the path from FC to FP was reversed. The 
Mplus code was changed to reflect this and the model was analyzed again to 
determine if the change in the path direction resulted in identical estimated 
covariance matrices and identical fit indices. 
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Figure 3.4 Test for equivalent models, hypothesized model 
(Hershberger, 2006) 
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Figure 3.5 Test for equivalent model, alternative model 
     (Hershberger, 2006) 
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CHAPTER IV 
Results 
Sample Characteristics 
Demographic characteristics of the study sample are summarized for each 
group in Table 4.1. The age of the study subsample ranged from 50 - 85 years 
old. The mean age in the no PAD group was 62.41 (SE = 0.190) and the mean 
age in the PAD group was 70.53 (SE = 0.834). Subjects were significantly older 
in the PAD group (p < .0001). The majority of the subjects in both groups were 
female. In the no PAD group (n = 3317), 47% of the sample was male and 52% 
of the sample was female. In the PAD group (n = 378), 44% of the sample was 
male and 56% of the sample was female.  
The majority of the sample for both groups was Caucasian (no PAD group 
79.5%, PAD group 79.8%) and most of the subjects were married (no PAD group 
68%, PAD group 53%, p < .0001). In the PAD group, a significantly larger 
percentage of the sample had less than a 9th grade education than those in the 
no PAD group (15.2% vs. 9.2%, p = .037). Most of the subjects in the no PAD 
group had a high school degree or above (75.7%), with 25.2% having a college 
degree or higher. Conversely, only 66% of the subjects in the PAD group had a 
high school degree or above, with only 15.2% of the sample having a college 
degree or higher, which was a significant difference (p = .0067) between the two 
groups.  Most of the sample for both groups reported an income level of below 
$44,000 (52.4% no PAD vs. 72.7% in the PAD group). There was a significant 
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difference between the two groups for an income level greater than $75,000 (no 
PAD 24.6% vs. PAD 10.3%, p = .0003). 
Age-adjusted frequencies of medical conditions listed by group in Table 
4.2. Crude, unadjusted frequencies are found in Table 4.3. For age 50 - 59 years 
old, subjects with no PAD had a lower rate of hypertension (34.39% vs. 51.35%), 
high cholesterol (43.40% vs. 62.48%), diabetes (8.0% vs. 15.78%) coronary 
artery disease (4.51% vs. 18.38%), congestive heart failure (2.44% vs. 4.55%) 
history of myocardial infarction (3.88% vs. 4.22%), angina (3.88% vs. 16.15%), 
and stroke (1.84% vs. 6.21%). Diabetic subjects in the no PAD group took more 
oral medication for blood glucose control than those with PAD (75.58% vs. 
39.03%). Subjects in the no PAD group were less likely to use insulin for treating 
diabetes than those with PAD (1.08% vs. 6.18%). Subjects with no PAD had a 
lower rate of obesity, defined as a BMI between 30 - 39, (27.05% vs. 32.86%) but 
a higher rate of morbid obesity, defined as a BMI > = 40, (4.92% vs. 1.88%) than 
those with PAD.  
For ages 60 and over, those with no PAD had a lower rate of hypertension 
(47.57% vs. 65.28%) high cholesterol (48.64% vs. 59.81%), diabetes (12.97% 
vs. 20.57%) congestive heart failure (6.23% vs.15.85%), stroke (7.09% 
vs.11.22%) and emphysema (5.95% vs. 9.74%). Angina was higher in the no 
PAD group than those with PAD (14.74% vs. 9.60%) and the rate of coronary 
artery disease was about the same for the no PAD and PAD groups (12.81% vs. 
12.68%). 
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Descriptive Analysis of Observed Exogenous Variable 
Ankle-Brachial Index (ABI) 
The ABI ranged from 0.91 - 1.66 in the no PAD group and from 0.23 - 0.90 
in the PAD group. A lower ABI value indicates more severe PAD. Subjects aged 
50 - 59 without PAD had a mean ABI of 1.13 (SE = 0.004) compared to 0.80 (SE 
= 0.020) in the PAD group. Subjects aged 60 and over without PAD had a mean 
ABI of 1.11 (SE = 0.003) compared to 0.76 (SE = 0.013) in the PAD group. There 
was a significant difference in ABI between the non-PAD and PAD groups after 
age-adjustment (Age 50 - 59 p = .0001, Aged 60+ p = .0001). Subjects with PAD 
had significantly lower ABIs regardless of age.  
Descriptive Analyses of Observed FC and FP Indicators 
Table 4.5 is an item analysis for the ADL questionnaire, summarizing the 
mean and standard errors for each group. Table 4.6 summarizes the age-
adjusted mean and standard error (SE) for each observed factor indicator for FC 
and FP by group.  
Functional Capacity Observed Indicators 
Lower Extremity Strength  
Strength scores ranged from 46 - 696.80 newton-meters in the no PAD 
group, and 87.80 - 494.20 newton-meters in the PAD group. The mean score for 
lower extremity strength in subjects aged 50 - 59 without PAD was 324.20 (SE = 
3.60) compared to 264.23 (SE =13.05) in the PAD group. For subjects aged 60 
and over without PAD, the mean score for strength was 259.72 (SE = 4.78) 
compared to 219.89 (SE = 5.04) in the PAD group. Differences in lower extremity 
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strength scores between the no PAD and PAD groups were significant for 
subjects aged 50-59 and age 60 and over (Age 50 - 59 p = .0001, Age 60+  
p = .0001). Subjects with PAD had significantly lower scores for lower extremity 
strength than those without PAD even after controlling for age.  
Calf Circumference 
 Calf circumference (cm) ranged from 18 - 61.60 cm in the no PAD group 
and 23.30 - 56.30 cm in the PAD group. Mean calf circumference (cm) in 
subjects aged 50 - 59 without PAD was 38.89 (SE = 0.160) and 37.07 (SE = 
0.856) in those with PAD. In subjects over age 60 without PAD, the mean calf 
circumference (cm) was 37.55 (SE  = 0.118) compared to 36.04 (SE = 0.247) in 
the PAD group. Calf circumference was significantly smaller in the PAD group 
than the non-PAD group, controlling for age (Age 50 - 59 p  = .0367, Age 60+  
p = .0001).  
Lower Extremity Sensory Impairment 
 The lower extremity sensory impairment score ranged from 0 - 6 in both 
groups. A higher score indicates increased sensory impairment. The mean lower 
extremity sensory impairment score for subjects aged 50-59 without PAD was 
1.41 (SE= .177) and 3.28 (SE=1.01) in the PAD group. In subjects over age 60 
without PAD, the mean score was 4.03 (SE= .324) compared to 4.62 (SE= .934) 
in the PAD group. Controlling for age, there was no significant difference (Age 
50-59 p=0.0683, Age 60+ p=0.5507) in sensory impairment in older adults with or 
without PAD.  
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Functional Performance Observed Indicators 
Usual Gait Speed 
Usual gait speed scores ranged from 1.64 - 61.20 seconds in the no PAD 
group and 3.94 - 50.60 seconds in the PAD group. The mean usual gait speed 
score in subjects aged 50 - 59 without PAD was 5.61 (SE = 0.052) seconds and 
6.45 (SE = .400) seconds in the PAD group. In subjects over age 60, the mean 
score in the no PAD group was 6.74 (SE = 0.081) seconds and 8.13 (SE = 
0.254) seconds. The difference in usual gait speed between no PAD and PAD 
groups was significant (Age 50 - 59 p = .0374, Age 60+ p = .0001) even after 
controlling for age.  
Physical Activity 
The self-reported, average daily level of physical activity score ranged 
from one to four in both groups. A higher value represents a higher physical 
activity level. The mean score for the average daily level of physical activity for 
subjects aged 50 - 59 without PAD was 1.98 (SE = 0.035) compared to 2.14  
(SE = 0.142) in the PAD group. For subjects aged 60 and over without PAD, the 
mean score was 1.97 (SE = 0.022) compared to 1.76 (SE = 0.041) for those 
subjects with PAD. There was a significant difference between the no PAD and 
PAD groups over age 60 (p = .0001), but there was no significant difference 
between groups for age 50 - 59 (p = .2741).  
Physical Function Questionnaire (PFQ) 
The individual total scores on the PFQ ranged from 13 - 52 for both 
groups. A higher score indicates worse function. The mean PFQ score for 
62 
subjects aged 50 - 59 in the no PAD group was 18.83 (SE = 0.440) compared to 
24.30 (SE = 1.92) in the PAD group. In subjects aged 60 and over, the mean 
physical function score in the no PAD group was 15.80 (SE = 0.132) compared to 
18.24 (SE = 0.350) in the no PAD group. There was a significant difference in 
physical function between the two groups, for ages 50 - 59 (p = .0001) and over 
the age of 60 (p = .0001). 
Multigroup Confirmatory Factor Analysis 
Testing for Measurement Invariance 
A multigroup analysis was performed in order to test the measurement 
model (Figure 3.2) for measurement invariance between the two groups (no PAD 
vs. PAD). A summary of these results is found in Table 4.7. The model was 
tested for three different degrees of measurement invariance: configural, metric, 
and scalar.  
Configural Invariance. The model was tested for configural invariance 
(model A) across the no PAD and the PAD groups. The factor means for 
functional capacity and functional performance were set to zero and the rest of 
the model was free to be estimated. The chi-square test of model fit yielded a 
chi-square value of 37.430 with 16 degrees of freedom. The RMSEA was 0.027, 
90% CI [0.016 - 0.038], the CFI was 0.956, and the SRMR was 0.025. All values 
of each fit statistic indicated a good fit of the model to the data (Cheung & 
Rensvold, 2002).  
Metric Invariance. Next, the model was tested for metric invariance 
(model B) across the no PAD and PAD groups. The factor loadings were held 
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equal across groups and the intercepts were free to be estimated. The chi-
square test of model fit yielded a chi-square value of 38.928 with 20 degrees of 
freedom. The RMSEA was 0.023, 90% CI [0.012, 0.033], the CFI was 0.961, and 
the SRMR was 0.028. All fit statistic values indicated a good fit of the model to 
the data (Cheung & Rensvold, 2002).   
Scalar Invariance. Next, the model was tested for scalar invariance 
(model C) across the no PAD and PAD groups. The factor loadings and 
intercepts were held equal across groups and the residuals were free to be 
estimated. The chi-square test of model fit yielded a chi-square value of 42.374 
with 24 degrees of freedom. The RMSEA was 0.020, 90% CI [0.010, 0.030], the 
CFI was 0.962, and the SRMR was 0.029. All fit statistics indicated a good fit of 
the model to the data (Cheung & Rensvold, 2002).   
Chi-Square Difference Testing. Results of the measurement invariance 
testing and chi-square difference testing are summarized in Table 4.7. Model B 
(metric) model was compared to Model A (configural) model and the chi-square 
difference statistic was 3.007 with four degrees of freedom and a p-value of .556. 
For Model C (scalar) compared to Model B, the chi-square difference statistic 
was 2.8155 with 4 degrees of freedom and a p-value of .589. Lastly, Model C 
was compared to Model A, and the chi-square difference statistic was 5.870 with 
8 degrees of freedom and a p-value of .662. All three p-values were non-
significant, which failed to reject the null hypothesis of no measurement 
invariance. This finding supports measurement invariance for the configural, 
metric, and scalar models between the no PAD and PAD groups. The results 
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were replicated using the MODEL=CONFIGURAL METRIC SCALAR command 
in Mplus 7.11 and found to be in agreement. 
Model Testing 
Latent Variable Model Indirect Effect Analysis 
Testing for indirect effects was performed in order to determine if the 
latent variable functional capacity is a mediator between the exposure variable 
PAD severity (ABI) and the latent variable functional performance. The mediation 
analysis with indirect effects based on counterfactuals (causal inference) was 
performed using Mplus version 7.2 (Muthen & Muthen, 2014). 
Standardized and unstandardized results are summarized in Figures 4.1 
and 4.2. In the no PAD group, single path estimates and standard errors were 
calculated for the latent variable model. The exogenous variables age, gender, 
and diabetes were included in the analysis. The total direct effect between ABI 
and FP was not significant with a standardized estimate of -0.286 (SE = 0.191), 
p = .135. The total indirect effect between ABI and FP had a standardized 
estimate of 0.249 (SE = 0.174), p = 0.154.  
In the PAD group, the standardized estimate for the total direct effect 
between ABI and FP was -1.202 (SE = 0.471), which was significant (p = .011). 
The standardized estimate for the indirect effect from ABI to FP through FC was 
also significant at -1.983 (SE = 0.924), p = 0.032. The MC 95% CI [0.1769, 
0.480] was significant as it did not include zero. 
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Figure 4.1 
PAD Group 
Indirect Effect Analysis 
FC 
FP PAD 
Severity 
*Standardized estimates
**Unstandardized estimates 
Direct effect (ABI à  FP) 
-1.202 (0.471), p = 0.011 * 
-31.132 (12.815), p = 0.015 ** 
Indirect effect (ABI à  FC à  FP) 
-1.983 (0.924), p = 0.032 * 
25.678 (12.328), p = 0.037 ** 
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Figure 4.2 
No PAD group 
Indirect effect analysis 
Multigroup Analysis: Comparison of Latent Variable Means 
MGA: Parallel Slopes 
To determine between-group differences in latent variable means while 
controlling for the exogenous variables, a parallel slopes model was tested. 
Please refer to the methods section for specific steps. For functional capacity, the 
between group mean difference was -0.506 (SE = 0.246), p = .258, and for 
FC 
PAD 
Severity 
FP 
*Standardized estimates
**Unstandardized estimates 
Indirect effect (ABI à  FC à  FP) 
0.249 (0.174), p = 0.154 * 
4.676 (3.241), p = 0.149 ** 
Direct effect (ABI à  FP) 
-0.286 (0.191), p = 0.135 * 
-5.373 (3.538), p = 0.129 ** 
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functional performance it was 1.141 (SE = 0.448), p = .011. In summary, there 
was no significant between-group difference in functional capacity mean after 
controlling for age, gender, and diabetes. There was a significant between-group 
difference in functional performance after controlling for age, gender, and 
diabetes. The model fit was acceptable with an RMSEA of 0.058, CFI 0.811, and 
SRMR of 0.069.  
MGA: Non-parallel Slopes 
To determine between-group differences in latent variable means with the 
effect of different values of the exogenous variables on the latent variable, a non-
parallel slopes model was tested. Please refer to the methods section for specific 
steps. The effect of age, gender, and severity of PAD were tested.  
Age. The effect of age on between-group differences in latent variable 
means is summarized in Table 4.9.  In both groups, functional capacity 
decreases with increasing age. The difference in the functional capacity means 
between the two groups also decreases with increasing age. The biggest 
difference appears to be at age 50, with the PAD group having worse functional 
capacity. In both groups functional capacity declines as age increases.  
In both groups, functional performance mean scores became higher with 
increasing age, representing a decline or worsening of performance. However, 
the PAD group had larger increases in functional performance mean scores than 
did the no PAD group by age 80. This reflects a worsening of functional 
performance decline with increasing age in the PAD group compared to the no 
PAD group. 
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ABI. This analysis was performed to determine the relationship between 
severity of PAD as determined by the ABI and the functional capacity and 
performance values. The results are summarized in Table 4.8. Functional 
capacity scores increased with higher ABI values. The biggest increase in the 
functional capacity score (from 5.609 to 9.706) was seen as the ABI increased 
from 0.20 (severe PAD) to 0.50 (moderate PAD).  
Functional performance scores increased, representing worse function, as 
ABI values decreased (low ABI values represents more severe PAD). The 
biggest decline in functional performance occurred from the 0.50 (moderate 
PAD) to the 0.20 (severe PAD) ABI. Both functional capacity and functional 
performance worsened with more severe PAD.  
Gender. The results for gender are summarized in Table 4.11. For 
functional capacity, the male and female differences were larger in the no PAD 
group. The differences in the no PAD and PAD groups were larger among males 
than females. Lastly, males had a higher functional capacity than females in both 
groups. For functional performance, males also had a higher functional 
performance than the females in both groups. 
Test for Equivalent Models 
As described in the methods section, the replacement rule (Hershberger, 
2006) was used to test for a possible equivalent model. One possible equivalent 
model was tested and is shown in Figure 3.5. The direction of the arrow 
connecting the FC and FP paths was reversed and analyzed in Mplus. 
Covariance matrices from the original model analysis (Figure 3.4) and the 
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possible equivalent model (Figure 3.5) were saved into separate files and 
compared. Results showed the estimated covariance matrices were not 
identical. The fit indices were also compared and were found to be identical. 
According to MacCallum, Wegener, Uchino, & Fabrigar (1993), identical fit 
indices can occur by chance even if the two models do not have identical 
covariance matrices. This appears to have occurred with this analysis, although 
the two models were found to have identical fit indices, the covariance matrices 
were not identical, therefore, the model tested in Figure 3.5 cannot be considered 
an equivalent model. It is acknowledged that other equivalent models could 
potentially exist, but additional investigation is beyond the scope of this 
dissertation.  
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CHAPTER V 
 DISCUSSION 
Key Study Findings 
The study of function in older adults with PAD has lacked the integration of 
a formal theoretical framework. Many studies have included evidence supporting 
bivariate relationships between salient variables, but formal investigation of a 
multivariate model has not been done. In fact, studies that have been guided by 
a theoretical framework in the PAD literature have largely focused on 
psychosocial constructs such as social-cognitive theory and self-efficacy. There 
has been little study of the mechanisms that connect PAD severity and functional 
capacity and performance in older adults with PAD.  
In this study, a multivariate, latent variable model of functional capacity 
and performance was developed and tested in older adults with and without 
PAD. The measurement model was tested for measurement invariance between 
the two groups, and configural, metric, and scalar invariance was demonstrated. 
Fit statistics for the measurement model showed good fit of the model to the 
data. Multigroup full structural equation modeling demonstrated a good fit of the 
model to the data as well. Indirect effect analysis of the latent variable model 
showed functional capacity to mediate the effect between PAD severity and 
functional performance in the PAD group only. Multigroup alignment analysis 
facilitated the estimation of between group differences in latent variable means. 
There was no significant difference in latent variable means between the PAD 
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and no PAD groups for functional capacity, however, there was a significant 
difference in means for functional performance. 
Review and Discussion of the Main Conclusions of the Study 
Sample characteristics  
The demographic characteristics of the study sample are consistent with 
previous studies. Given that the presence of even mild PAD is a marker for 
cardiovascular disease, increased prevalence of cardiovascular risk factors are 
expected in the PAD group. Many studies have demonstrated the presence of 
increased cardiovascular risk factors in older adults with PAD (Reis, Michos, von 
Muhlen, & Miller, 2008, Collins, Petersen, Suarez-Almazor, & Ashton, 2003).  
The finding that African-Americans in the sample were more likely to have 
PAD compared to no PAD is also a finding documented in the literature. This 
disparity is also present in the treatment of African-Americans with PAD. For 
example, African-American patients are more likely to undergo lower extremity 
amputation for treatment of PAD than whites (Huber, Wang, Wheeler, 
Cuddeback, Dame, & Ozaki, et al., 1999). The disparity is alarming: African-
Americans in the Medicare population from 2003 - 2005 had a four-times higher 
rate of amputation for PAD than whites (Fisher, Goodman, Chandra, Bronner, & 
Brownlee, 2008).   
The finding of lower education level and income level in subjects with PAD 
is supported by previous literature. Low socioeconomic status as partially defined 
by income and education level is also associated with the presence and severity 
of PAD (Feinglass, Kaushik, Handel, Kosifas, Martin, & Pearce, 2000). According 
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to one study, the odds of having a lower extremity amputation were significantly 
increased if you were African-American, had a low-income, were over the age of 
64, and had diabetes or other cardiovascular comorbidities (Feinglass, et al.,  
2000). 
Subjects with PAD were less likely to be obese (BMI 30 - 39) or morbidly 
obese (BMI > 40) than those without PAD. Body mass index (BMI) was 
significantly greater in the no PAD group. This finding is consistent with other 
studies that have not found a significant association between BMI and PAD 
prevalence, or, have found an inverse relationship (Ix, Allison, Denenberg, 
Cushman, & Criqui, 2008). Instead, Ix, et al., (2008), found a greater association 
between waist to hip ratio risk of future cardiovascular events than BMI in older 
adults with PAD. The lack of association between BMI could be explained by the 
general poor health and loss of muscle mass in older adults with PAD.  
Individual Latent Variable Indicators  
Functional Capacity Indicators 
Lower extremity strength. Reductions in lower extremity strength occur 
with the normal ageing process (Samuel & Rowe, 2009). The results of this study 
showed that lower extremity strength is significantly reduced in older adults with 
PAD compared to those in the no PAD group. This significant difference in lower 
extremity strength between the two groups was also present after age 
adjustment. This finding is expected and consistent with previous studies. For 
example, Scott-Okafor, et al., (2001) compared lower extremity strength in a PAD 
and no PAD group and found the PAD group to have significantly decreased 
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lower extremity strength compared to the no PAD group. And in 2008, 
McDermott, et al., studied lower extremity strength in older adults with PAD as 
measured by knee extensor strength. Subjects with PAD had significantly 
decreased lower extremity strength compared to subjects without PAD. 
Calf circumference. The measure of maximum calf circumference was 
significantly smaller in the PAD group compared to the no PAD group. This 
difference remained significant after adjustment for age. This finding is expected 
for several reasons. First, older adults with PAD have higher prevalence of 
hypertension, high cholesterol, diabetes, and heart disease, in addition to several 
other medical comorbidities. This indicates that overall health is worse than those 
without PAD. Older adults in poor health are less likely to engage in physical 
activity, have worse lower extremity strength, and therefore, less muscle mass.  
This is supported by histologic studies that have demonstrated increased cell 
death in the calf muscle, reduced numbers of Type I and Type II calf muscle 
fibers, and reduced cross-sectional fiber area in subjects with PAD (Mitchell, 
Duscha, Robbins, Redfern, Chung, Bensimhon, & Kraus, et al, 2007; Askew, 
Green, Walker, Kerr, Green, Williams, & Febbraio, 2005). Decreased calf 
perfusion in subjects with PAD and decreased numbers of capillaries in muscle 
fibers has also been documented (Askew, et al., 2005). The significantly smaller 
maximum calf circumference in the PAD group is likely a combination of 
histological changes that occur as a result of PAD as well as deconditioning and 
muscle loss due to as a result of disuse.  
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Lower extremity sensory impairment. The results of this study showed 
that there was a significant difference in degree of sensory impairment between 
the PAD and no PAD groups. After adjustment for age, there was no significance 
between the two groups with regards to degree of sensory impairment. 
Comparing our results to the literature is difficult given that few studies evaluated 
for sensory impairment using monofilament testing. One study (McDermott, 
Criqui, Greenland, Guralnik, Liu, Pearce, & Taylor, et al., 2004) mentioned 
monofilament testing in the methods section of the paper, but no results were 
documented. However, impairment of sensory nerves in older adults with PAD 
has been studied using other methods of diagnosis, including quantitative 
sensory testing (QST), thermal testing, and mechanical testing (Lang, Schober, 
Rolke, Wagner, Offenbacher, & Treede, et al., 2006). This study showed 
significant differences in degree of sensory impairment between subjects with 
both moderate and severe PAD and a group without PAD, even after controlling 
for diabetes.  
The significant difference between the two groups disappeared after 
controlling for age indicating that monofilament testing may not be sensitive 
enough to differentiate between normal age-related changes in sensation and 
pathologic impairment due to PAD.  
Functional Performance Indicators 
Usual gait speed.  The usual gait speed as measured by the 20-foot 
walk, was significantly slower in the PAD group compared to the no PAD group. 
This difference remained after adjustment for age. This finding is similar to other 
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studies that have evaluated usual gait speed in older adults with PAD. Scherer, 
Bainbridge, Hiatt, & Regensteiner, 1998) reported significantly slower usual gait 
speeds in older adults with PAD compared to a control group without PAD. 
Similarly, Crowther, Spinks, Leicht, Quigley, & Golledge (2007) found usual gait 
speed to be significantly slower in subjects with PAD compared to a control 
group without PAD. The slower usual gait speed may be due to changes in gait 
patterns such the adaptation of a shuffling gait in older adults with PAD 
(Crowther, et al., 2007). Alterations in movement at the hip and ankle joints have 
also been demonstrated (Chen, Pipinos, Johanning, Radovic, Huisinga, Myers, & 
Stergiou, 2008). Pain in the lower extremities present in a large percentage of 
patients with PAD, is presumed to aggravate and exacerbate impairments in gait. 
Physical function. Physical function as measured by a 13-item 
questionnaire, was significantly higher in the PAD group compared to the no PAD 
group indicating a decreased ability to perform day-to-day functional tasks. This 
difference remained significant after age adjustment. This is expected and similar 
to findings reported previously in the literature. Izquierdo-Porrera, Gardner, 
Bradham, Montgomery, Sorkin, & Powell, et al., (2005) found subjects with PAD 
to report perceived decreased ability to perform daily functional tasks.   
Physical activity. Average level of self-reported physical activity was 
significantly lower in the PAD group compared to the no PAD group.  After 
adjustment for age subjects aged  
50 - 59 with PAD had a significantly higher level of physical activity compared to 
those without PAD group. This finding may be due to a small sample size in the 
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PAD group (n = 36) aged 50 - 59.  However, subjects over the age of 60 with 
PAD had a significantly lower level of physical activity compared to the no PAD 
group.  
This finding is similar to other studies of physical activity in older adults 
with PAD. Gardner & Clancy (2006) studied self-reported leisure-time physical 
activity in a group of older adults with PAD. This study found that subjects with a 
higher mean ABI and less severe PAD had higher levels of mean leisure-time 
physical activity compared to subjects with a lower ABI and more severe PAD. 
Gardner, Montgomery, Scott, Afaq, & Blevins (2007) assessed level of daily 
physical activity over seven days in a group of older adults with PAD compared 
to a group without PAD with a step activity monitor.  Subjects with PAD had 
significantly lower levels of physical activity than the group without PAD, which 
remained significant after adjustment for age and other covariates. 
Summary of Latent Variable Indicators Descriptive Statistics 
Functional capacity indicators. Older adults with PAD had significantly 
decreased lower extremity strength and smaller maximum calf circumference 
measures than the group without PAD. These findings are expected and 
consistent to previous studies.  
Functional performance indicators.  Older adults with PAD had 
significantly slower usual gait speed than those without PAD.  The mean usual 
gait speed was 0.77 m/s in the PAD group. A commonly reported cutoff indicating 
high risk for health-related outcomes is gait speed less than 1 m/s (Cesari, 
Kritchevsky, Penninx, Nicklas, Simonsick, & Newman, et al., 2005). The level of 
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physical activity and ability to perform ADLs was also significantly lower in the 
PAD group compared to the no PAD group. This is also expected and consistent 
with previous studies.  
Latent Variable Model 
The main purpose of this dissertation was to create and develop a latent 
variable model of functional capacity and functional performance in older adults 
with PAD. The relationship between PAD severity, FC, and FP was also of 
primary interest in this study. 
Figure 5.1 Latent Variable Model 
Model Testing 
Multigroup Analysis: Measurement Model 
Multigroup analysis was performed in order to determine if the proposed 
measurement model of FC and FP could be used to compare the PAD and no 
PAD groups.  The model was tested in each group separately first and showed 
good fit for both. Next, the proposed model was tested for measurement 
invariance between the two groups. The analysis demonstrated configural, 
metric, and scalar invariance between the two groups. This means that the 
PAD 
Severity 
FC 
FP 
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relationships of the observed latent variable indicators to the latent variable are 
the same between the two groups. The two groups can still have different means 
and variances, but the inference after demonstrating measurement invariance is 
that the differences will be through the common latent variable (Millsap & Olivera, 
2012). Demonstrating invariance of the measurement model between the two 
groups allowed for meaningful group comparisons of the full structural model to 
be made.  
Full SEM Analysis 
Model Fit 
Multigroup analysis was performed on the full structural model and the 
detailed results are found in Chapter 4. The salient results will be discussed next. 
Latent Variable Means 
One of the more substantively interesting results yielded from this study is 
that the analysis provided an avenue for obtaining the difference between latent 
variable means. The FC mean was smaller in the PAD group compared to the no 
PAD group, but not significantly smaller. This could be due to the indicator 
measures, especially for calf circumference and lower extremity sensory 
impairment. The FP mean was significantly smaller in the PAD group compared 
to the no PAD group. It is expected that the group without PAD would have a 
higher FP than the group with PAD. This analysis allows quantification of latent 
variables FC and FP, which has not been evaluated in the literature at the time of 
this dissertation.  
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Indirect Effect Analysis 
The indirect effect analysis enabled testing of the hypothesis that 
functional capacity mediates the relationship between the exposure variable PAD 
severity and functional performance. It did show that there is a significant direct 
effect between PAD severity and functional performance as well as a significant 
indirect effect through functional capacity. As discussed in the results section, 
there is both a direct and indirect effect of PAD severity on functional 
performance. From a clinical perspective, this allows for two possible areas of 
intervention to increase functional performance in older adults with PAD. If there 
is a direct effect of the severity of PAD on functional performance, then 
interventions to increase lower extremity blood flow should increase functional 
performance. Past research has shown that angioplasty or bypass surgery alone 
does not result in long-term increases in functional performance. There is a 
significant indirect effect as well through functional capacity. Again, past 
interventions that solely focused on strength or endurance training did not result 
in long term improvements in FP either. Perhaps a coordinated intervention to 
improve blood flow followed by long term strength and endurance training to 
increase capacity is the answer for long term improvements in functional 
performance. Longitudinal studies are the best avenue for testing the efficacy of 
such an intervention.  
Equivalent Models 
The possibility of equivalent models was investigated as part of this 
dissertation. It is worth noting that that the existence of alternative or equivalent 
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models in SEM analysis is recognized as fairly common. One large review study 
evaluated 79 published SEM reports over a 20-year period from 1984 - 2004 
(Henley, Shook, & Peterson, 2006). This review study reported that 75% of the 
models reviewed had at least one equivalent model as evaluated by the 
replacement rule. It is acknowledged that the analysis for this study was not a 
comprehensive search potential equivalent models, and therefore, such models 
may still exist. 
Study Limitations 
There are several limitations to this study. First, this study was a 
secondary analysis and therefore limited by the measures available in the 
dataset. For example, a better measure of functional capacity would strengthen 
this research.  Similarly, the Semmes-Weinstein monofilament test is useful for 
sensory impairment screening, but not for motor nerve impairment or diagnosis 
of peripheral neuropathy. And lastly, physical activity was self-reported and 
measured by questionnaire in this study. A physical activity monitor used to 
measure physical activity was not included in the NHANES survey cycles used in 
this study (1999-2002).  
The second limitation relates to sources of specification error. These 
include possible omitted variables, measurement error, and reverse causation. 
Omitted variables. There is a high likelihood of omitted variables in the 
hypothesized model. It is acknowledged that omitted variables can result in 
biased parameter estimates and standard errors (Tomarken & Waller, 2005). 
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Future studies can include sensitivity analyses to determine the effect of the 
omitted variable(s) on the model.  
Measurement error. Measurement error in the causal variable (PAD severity 
measured by ABI) can result in biased estimates of its effect. Even though the 
sensitivity and specificity of the ABI are both greater than 90%, even small 
amounts of measurement error can result in biased estimates. One way the 
effect of this measurement error is reduced is by the use of multiple indicators for 
each latent variable.  
Reverse causation. The possibility of reverse causation is also a mechanism for 
specification error. Reverse causation was not formally tested in this study and 
can be done in future studies. Theoretically, the idea of reverse causation in this 
model does not make sense. The hypothesized causal effect in this study is that 
PAD severity has a causal effect on functional capacity and functional 
performance in older adults with PAD. Reverse causation indicates that 
functional capacity and functional performance have a causal effect on the 
severity of PAD. While this was not tested, it does not make conceptual sense. 
Additionally, if both causal directions are specified the model would have a 
feedback loop and would not be identified.  
Third, analysis of lower order model components (path coefficients and 
variance explained) was not a specific aim of this study and therefore not 
included in the analysis and interpretation of the data. Future studies can focus 
on a study of the lower order model components and predicting variance 
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explained using appropriate methodology if indicated (Hayduk, Cummings, 
Boadu, Pazderka-Robinson, & Boulianne, 2007).  
A fourth limitation of the study involves the degree of PAD severity in the 
study sample (PAD group, n=378). The mean ABI of the PAD group was 0.76 
(range 0.23-0.89). This mean ABI value represents mild-moderate PAD. An ABI 
of less than 0.50 would indicate severe PAD. Overall, 262 subjects fell into the 
mild-moderate PAD group, and 116 fell into the severe PAD group. There were 
not enough subjects in the severe PAD group for adequate power to run a 
multigroup analysis. Instead, two groups were created, PAD and no PAD. Future 
studies should evaluate the model in subjects with mild to moderate and severe 
PAD to capture the effect of all levels of PAD severity on functional capacity and 
functional performance.  
Significance of Study Findings 
The most significant contribution of this research is the application of 
multivariate, latent variable modeling to the study of function in older adults with 
PAD. The attempt to identify indicators of functional capacity and functional 
performance and thereby providing definition, measurement, and substantive 
value to them has not been done before. This research should be viewed as a 
stepping-stone for future research and evaluation of the complex problem of 
function in older adults with PAD.  
While the contributions of this study are largely methodological, there is 
applicability to nursing practice now. Specifically, this study provides confirmation 
that in older adults with PAD, the effect of PAD severity on functional 
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performance is mediated through functional capacity. The inference is that 
interventions should focus on increasing capacity in order to increase 
performance. Given that there is both a direct and indirect effect, a study 
combining both an intervention to improve blood flow followed by a long-term 
strength and endurance program is the answer to sustained improvements in 
functional performance.  
The mean usual gait speed in the PAD group suggests high risk for future 
disability, even with a mean ABI of 0.76, or mild to moderate PAD. Interventions 
to increase functional capacity in older adults with mild to moderate PAD can 
likely improve functional performance and perhaps even prevent or prolong 
future disability.  
Future Study and Next Steps 
 Further study is needed to replicate the findings of this study. Next steps 
should include further refinement of the model and testing in other samples. 
Refinement of the model should include more definitive measures of functional 
capacity as well as better measures for sensory impairment and physical activity. 
The role of lower extremity pain in this process also needs to be delineated.  
As discussed in the limitation section, groups were divided into a PAD 
group and no PAD group. Future studies should further break down the PAD 
group to differentiate between mild, moderate, and severe PAD in order to 
extract differences in the model and latent variable interactions. And finally, a 
longitudinal study of the effect of PAD severity on functional capacity and 
functional performance should be conducted in order to see changes over time. 
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To determine if increases in functional capacity result in functional performance 
increases, an intervention study should be conducted. Aggressive, early 
intervention is of particular interest given that older adults with mild-moderate 
PAD are at high risk for future disability.
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Table 3.2. 
Missing data for No PAD group, Strength variable 
Reason for Missing 
Value               n (%) 
General Exclusions: 
Safety exclusion 
SP refusal 
No time 
Physical limitation 
Communication problem 
Equipment failure 
SP ill/emergency 
Interrupted 
Came late/left early 
Other 
Excluded for: 
Chest/Abdomen surgery last 3 weeks 
Myocardial infarction 
Told by Dr had brain aneurysm or 
stroke 
Severe neck or back pain 
Difficulty bending/straightening 
right knee 
Had right knee or right hip 
replacement 
Total Missing Values 
250 (7.5) 
49 (1.5) 
17 (0.5) 
248 (7.5) 
9 (0.3) 
51 (1.5) 
19 (0.6) 
1 (0.1) 
144 (4.3) 
64 (1.9) 
18 (0.5) 
8 (0.2) 
144 (4.3) 
101 (3.0) 
62 (1.9) 
64 (1.9) 
  1249 (37) 
SP=sample person 
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Table 3.3. 
Missing data for PAD group, strength variable 
Reason for Missing 
Value n (%) 
General Exclusions: 
Safety exclusion 
SP refusal 
No time 
Physical limitation 
Equipment failure 
SP ill/emergency 
Came late/left early 
Other 
Excluded for: 
Chest/Abdomen surgery last 3 weeks 
Myocardial infarction 
Told by Dr had brain aneurysm or 
stroke 
Severe neck or back pain 
Difficulty bending/straightening 
right knee 
Had right knee or right hip 
replacement 
Total Missing Values 
32 (8.5) 
5 (1.3) 
3 (0.8) 
30 (7.9) 
3 (0.8) 
1 (0.3) 
11 (2.9) 
5 (1.3) 
1 (0.3) 
1 (0.3) 
14 (3.7) 
13 (3.4) 
9 (2.4) 
9 (2.4) 
137 (36) 
SP=sample person 
87 
Table 4.1. 
Unadjusted demographic characteristics of sample by group 
No PAD Group 
(n=3317) 
PAD Group 
(n=378) 
p-value 
Age (years) 
Gender  
     Male (n, %) 
     Female (n, %) 
Body Mass Index 
Systolic blood pressure 
(mm/Hg) 
Diastolic blood pressure 
(mm/Hg) 
60-second heart rate 
Ethnicity (n, %) 
Non-Hispanic white 
Non-Hispanic black 
Mexican American 
Other Hispanic 
Other racial/multi-        
racial 
Marital Status (n, %) 
Never Married 
Married 
              62.41  (.190) 
1689   (47.1) 
1628   (52.9) 
28.38   (.173) 
   132.86   (.849) 
72.79   (.617) 
69.99   (.387) 
1864   (79.5) 
523     (7.6) 
680     (3.5) 
151     (5.4) 
         99     (3.9) 
126     (3.6) 
202  (68) 
   70.53  (.834) 
190    (44.0) 
188    (56.0) 
             27.34    (.348) 
           144.84  (2.322) 
 66.78  (1.166) 
 72.53  (1.085) 
216    (79.8) 
90       (13) 
56      (2.6) 
13      (3.8) 
3      (0.8) 
11      (2.9) 
186    (53.3) 
     <0.0001 
0.0078 
<0.0001 
<0.0001 
0.0286 
0.7663 
<0.0001 
0.0106 
0.3877 
0.0216 
0.4699 
<0.0001 
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Divorced 
Widowed 
Separated 
Living with Partner 
Education (n, %) 
Less than 9th grade 
9 -11th grade 
High school   
grad/GED 
Some college/  
Associates  
College grad or  above 
Income (n, %) 
0-4,999 
5,000-9,999 
10,000-14,999 
15,000-19,999 
20,000-24,999 
25,000-34,999 
35,000-44,999 
45,000-54,999 
55,000-64,999 
           65,000-75,000 
          75,000 and over 
328     (11.4) 
506     (12.9) 
           96      (2.0) 
        64      (2.1) 
   668       (9.2) 
  556     (15) 
734  (25.2) 
719  (25.3) 
633   (25.2) 
32    (0.8) 
214    (5.6) 
334    (8.4) 
244    (6.8) 
245    (7.1) 
384  (12.4) 
292  (10.0) 
234    (9.7) 
179    (7.4) 
143    (5.9) 
517   24.6) 
35    (12.8) 
   115     (28.0) 
       11 (2.1) 
         2 (0.8) 
94  (15.2) 
78  (18.9) 
95  (30.7) 
59  (20.1) 
50  (15.2) 
       10    (1.7) 
43  (11.0) 
49  (15.4) 
40    (9.8) 
26    (8.6) 
60  (18.3) 
26    (7.9) 
22    (7.1) 
11    (5.1) 
7    (2.8) 
32  (10.3) 
0.7655 
<0.0001 
0.9861 
0.0814 
0.0370 
0.0687 
0.2072 
0.0075 
0.0067 
0.0077 
0.0005 
0.0970 
0.0333 
0.7989 
0.0187 
0.2430 
0.4303 
0.0511 
0.0309 
0.0003 
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Table 4.2. 
Medical comorbidities by group, age-adjusted 
      No PAD Group 
%, SE 
         PAD Group 
%, SE 
No PAD Group 
%, SE 
PAD Group 
%, SE 
Age 50-59       Age 50-59   Age 60+         Age 60+ 
Hypertension  
High Cholesterol 
Diabetes 
     Taking Oral medication 
     Taking Insulin  
34.39  (1.99) 
43.40  (1.64) 
8.00  (.849) 
75.58  (5.57) 
1.08  (0.30) 
51.35 (11.38) 
62.48 (12.49) 
15.78  (9.38) 
39.03  (9.43) 
6.18  (4.70) 
47.57 (1.24) 
48.64 (1.27) 
12.97 (.780) 
71.01 (2.63) 
3.81 (0.60) 
65.28 (2.49) 
59.81 (3.23) 
20.57 (2.64) 
60.40 (7.10) 
10.71 (2.73) 
Coronary Artery Disease 
Congestive Heart Failure 
Myocardial Infarction 
Angina 
Stroke 
Emphysema 
Arthritis 
-Osteoarthritis 
Cancer 
Liver disease 
Current Cigarette Smoker 
Smoked minimum 100 
cigarettes  
 4.51  (.681) 
2.44  (.610) 
3.88  (.752) 
3.88  (.726) 
1.84  (.470) 
2.37  (.539) 
54.95  (5.18) 
8.96  (.924) 
5.06  (.735) 
65.41  (1.75) 
56.64  (1.64) 
18.38  (8.30) 
4.55  (2.54) 
  4.22  (2.41) 
16.15  (7.90) 
6.21  (4.16) 
1.19 (1.20) 
46.57 (21.96) 
9.19   (6.19) 
6.67   (4.75) 
60.47 (11.58) 
82.85   (7.86) 
12.81 (1.53) 
6.23 (1.10) 
11.64 (1.31) 
14.74 (1.95) 
7.09 (1.32) 
5.95 (1.27) 
68.63 (3.00) 
20.45 (.918) 
3.18 (.622) 
60.15 (1.41) 
51.55 (1.63) 
12.68 (4.55) 
15.85 (4.85) 
12.87 (4.95) 
9.60 (3.99) 
11.22 (4.39) 
9.74 (4.67) 
53.59 (9.36) 
19.75 (3.12) 
2.65 (.701) 
53.25 (2.84) 
67.70 (3.31) 
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Obesity, BMI >=30, <=39 
Morbid Obesity, BMI >40 
27.05  (1.61) 
4.92  (0.91) 
32.86 (10.42) 
1.88   (1.89) 
27.55 (1.21) 
2.79 (0.41) 
22.64 (2.42) 
3.52 (1.20) 
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Table 4.3. 
Medical comorbidities by group, unadjusted 
No PAD Group 
(n=3317) 
Frequency (%, SE) 
    PAD Group 
      (n=378) 
Frequency (%, SE) 
p 
Hypertension 
High Cholesterol 
Diabetes 
     Taking Oral medication 
     Taking Insulin  
Coronary Artery Disease 
Congestive Heart Failure 
Myocardial Infarction 
Angina 
Stroke 
Emphysema 
Osteoarthritis 
Rheumatoid Arthritis 
Current Cigarette Smoker 
Smoked minimum 100 cigarettes 
Obesity, BMI >=30, <=39 
Morbid Obesity, BMI >40 
1468 (41.3) 
1278 (45.9) 
466 (10.4) 
342 (72.6) 
102   (2.5) 
243  (7.3) 
140  (3.4) 
225  (6.3) 
213  (6.4) 
150  (3.7) 
107  (3.7) 
325 (31.6) 
413 (56.3) 
497 (30.6) 
1750 (53.9) 
909 (27.3) 
112   (3.8) 
         230   (62.5) 
         164   (59.4) 
           84   (19.3) 
           57   (57.4) 
           33      (10) 
           49  (14.5) 
           37    (9.3) 
           52  (13.7) 
           29    (9.5) 
           41  (10.4) 
           24       (7) 
          51   (44.1) 
          44   (49.1) 
          90   (35.2) 
        257   (70.3) 
         77    (24.5) 
         11      (3.2) 
p<0.0001 
p=0.0210 
p<0.0001 
p=0.3293 
p<0.0001 
p=0.0001 
p<0.0001 
p<0.0001 
p=0.4058 
p<0.0001 
p=0.0029 
p=0.0856 
p=0.1477 
p=0.0353 
p<0.0001 
p=0.0099 
p=0.8185 
Cancer  471   (15)          67    (17.9) p=0.0789 
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Table 4.4. 
Physical Function Questionnaire Item Means, Standard Error 
PFQ Item 
(all items 1-4 scale) 
No PAD Group 
(n=3317) 
PAD Group 
(n=378) 
p 
Difficulty walking 2 or 3 blocks 
Difficulty walking up 10 steps 
Difficulty stooping, crouching, kneeling 
Difficulty lifting and carrying 10 pounds 
Difficulty performing household chores 
Difficulty preparing own meals 
Difficulty walking between rooms on same floor 
Difficulty standing up from armless chair 
Getting in and out of bed difficulty 
Difficulty dressing yourself 
Difficulty going to movies or events 
Difficulty attending social event 
Difficulty doing leisure activities at home 
Mean (SE) 
1.41 (.022) 
1.73 (.031) 
1.38 (.025) 
1.30 (.021) 
1.34 (.020) 
1.12 (.011) 
1.08 (.008) 
1.26 (.017) 
1.19 (.014) 
1.13 (.010) 
1.25 (.018) 
1.20 (.018) 
1.08 (.009) 
Mean (SE) 
1.93 (.085) 
2.08 (.065) 
1.62 (.052) 
1.56 (.059) 
1.59 (.060) 
1.25 (.048) 
1.17 (.031) 
1.48 (.037) 
1.23 (.033) 
1.21 (.044) 
1.44 (.051) 
1.31 (.043) 
1.11 (.024) 
<0.0001 
<0.0001 
  0.0006 
<0.0001 
<0.0001 
  0.0002 
  0.0002 
  0.0001 
0.3092 
  0.0108 
  0.0002 
  0.0298 
  0.2419 
Note: All items scored range 1-4 (1=no difficulty, 2=some difficulty, 3=much difficulty, 4=not able to do) 
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Table 4.5. 
Age-adjusted factor indicator means, standard errors by group 
           No PAD  PAD   No PAD  PAD               p 
  (Age 50-59, Age 60+)
Age 50-59        Age 60+ 
No PAD Group PAD Group No PAD Group PAD Group 
Mean, SE Mean, SE Mean, SE Mean, SE 
Functional Capacity Indicators 
Lower Extremity Strength 
(Newton-Meters) 
         324.20 (3.60)         264.23 (13.05) 259.72 (4.78) 219.89 (5.04) p=0.0001, p=0.0001 
Lower Extremity Sensory 
Impairment 
1.41 (.177) 3.28  (1.01) 4.03 (.324) 4.62 (.934) p=0.0683, p=0.5507 
Calf Circumference (cm2) 38.89 (.160)             37.07 (.856) 37.55 (.118) 36.04 (.247) p=0.0367, p=0.0001 
Functional Performance 
Indicators 
Usual Gait Speed (seconds)              5.61 (.052)  6.45  (.400)             6.74 (.081) 8.13 (.254) p=0.0374, p=0.0001 
Daily level of physical activity 1.98 (.035) 2.14  (.142) 1.97 (.022) 1.76 (.041) p=0.2741, p=0.0001 
Physical Function 18.83 (.440) 24.30  (1.92) 15.80 (.132) 18.24 (.350) p=0.0057, p=0.0001 
Exogenous Variable 
Ankle-Brachial Index 1.13 (.004) 0.80  (.020) 1.11 (.003) 0.76 (.013) p=0.0001, p=0.0001 
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Table 4.6. 
Multigroup CFA: Model Invariance Testing 
Model 
Nested 
MLR 
Chi-
square 
(df) 
Comparison 
MLR 
Chi-square 
(df) 
Scaling 
Correction 
Factor 
(nested, 
comparison) 
RMSEA 
[90% CI] 
CFI SRMR Diff test 
Scaling 
Correction 
Factor 
(Cd) 
TRd 
(df) 
p 
A 
B 
C 
B vs. A 
C vs. B 
C vs. A 
- 
- 
- 
38.928 
42.374 
42.374 
37.430 
38.928 
42.374 
37.430 
38.928 
37.430 
     1.4447 
     1.5360 
     1.4980 
     1.5360 
     1.4447 
     1.4980 
     1.5360 
     1.4980 
     1.4447 
0.027 
[.016-.038] 
0.023 
[.012-.033] 
0.020 
   [.010-.030] 
- 
- 
- 
0.956 
0.961 
0.962 
- 
- 
- 
0.025 
0.028 
0.029 
- 
- 
- 
- 
- 
- 
1.902 
1.308 
1.603 
- 
- 
- 
3.0077 
(4) 
2.8155 
(4) 
5.870 
(8) 
- 
- 
- 
0.556 
0.589 
0.662 
Model A=configural invariance, Model B=metric invariance, Model C=scalar invariance 
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Table 4.7. 
Expected differences in FC and FP given PAD severity 
0 0.20 
(Severe) 
0.50 
ABI 
0.70 
(Mild-
Mod) 
0.90 
(Mild) 
0.91 
(Normal) 
1.0 
Functional 
Capacity 
Intercept 
No PAD 
Group 
PAD Group 
- 
2.878 
- 
5.609 
- 
9.706 
- 
12.437 
- 
15.168 
16.205 
- 
17.808 
- 
Functional 
Performance 
Intercept 
No PAD 
Group 
- - - - - -1.940 -2.132 
PAD Group 3.697 2.5096 0.728 -0.458 -1.646 - - 
ABI factor loading FC= 13.656, FP= -5.937, Calculation FC, no PAD group= 0 + 17.808*ABI, PAD group= 2.878 
+13.6565*ABI, Calculation FP, No PAD= 0 + -2.132*ABI, PAD= 3.697 + -5.937*ABI 
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Table 4.8. 
Effect of age on mean intercept differences for FC and FP 
Age 0 50 60 70 80 
Functional Capacity 
(FC) 
Factor Loading 
(FL) 
No PAD Group 
PAD Group 
-0.454 
-0.231 
-22.70 
 -28.475 
-27.24 
  -30.785 
     -31.78 
-33.095 
   -36.32 
-35.095 
Functional 
Performance (FP) 
No PAD Group 
PAD Group 
0.070 
0.114 
 3.5 
 -11.225 
 4.2 
  -10.085 
4.9 
   -8.945 
5.6 
   -7.805 
Calculations for FC, no PAD group= 0 + FL*age, PAD group= -16.925 + FL*age, for FP, no PAD group= 0 + FL*age, PAD 
group= -2.354 + FL*age 
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Table 4.9. 
Effect of gender on FC and FP scores 
Female Male 
Functional Capacity 
No PAD Group 
PAD Group 
Functional 
Performance 
0 
0.188 
9.904 
4.795 
No PAD Group 
PAD Group 
0 
0.782 
-0.362 
-0.453 
No PAD Group equation: FC = 0 +9.904 (male) –coef (age) + coef (abi) = 9.904, PAD 
Group equation: FC = 0.188 + 4.795 (male) –coef (age) + coef (abi)= 4.983 
No PAD-PAD difference, males: 9.904 – 4.983= 4.921 
No PAD Group equation: FP = 0+ -0.362 (male) –coef (age) + coef (abi) = -0.362 
PAD Group equation: FP = 0.782 + -0.453 (male) - coef (age) + coef (abi) = -0.329 
The No PAD-PAD group difference, males: -0.362 - -0.329 = -0.03 

12/3/98 Questionnaire:SP
Target Group: SP 1+
PHYSICAL FUNCTION QUESTIONNAIRE  
BOX 1A
CHECK ITEM PFQ.001:
IF AGE OF SP IS >= 20, GO TO PFQ.048
OTHERWISE, CONTINUE WITH BOX 1B.
BOX 1B
CHECK ITEM PFQ.002:
IF SP <= 4, CONTINUE.
OTHERWISE, GO TO PFQ.020.
PFQ.010 The next set of questions is about limitations caused by any long-term physical, mental or emotional problem
or illness.  Please do not include temporary conditions, such as a cold.
Is {SP} limited in the kind or amount of play activities {he/she} can do because of a physical, mental or
emotional problem?
YES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
NO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 (PFQ.020)
REFUSED . . . . . . . . . . . . . . . . . . . . . . . . . 7 (PFQ.020)
DON'T KNOW . . . . . . . . . . . . . . . . . . . . . . 9 (PFQ.020)
PFQ.015 Is {SP} able to take part at all in the usual kinds of play activities done by most children {his/her} age?
YES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
NO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
REFUSED . . . . . . . . . . . . . . . . . . . . . . . . . 7
DON'T KNOW . . . . . . . . . . . . . . . . . . . . . . 9
PFQ.020 {Do you/Does SP} have an impairment or health problem that limits {your/his/her} ability to {crawl, walk or
play} {walk, run or play} {walk or run}?
CAPI INSTRUCTION:
IF CHILD'S AGE = 1-4, DISPLAY "CRAWL, WALK OR PLAY".  IF CHILD'S AGE = 5-15, DISPLAY "WALK,
RUN OR PLAY".  IF SP'S AGE = 16-19, DISPLAY "WALK OR RUN".
YES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
NO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 (BOX 1BB)
REFUSED . . . . . . . . . . . . . . . . . . . . . . . . . 7 (BOX 1BB)
DON'T KNOW . . . . . . . . . . . . . . . . . . . . . . 9 (BOX 1BB)
APPENDIX B
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PFQ.030 Is this an impairment or health problem that has lasted, or is expected to last 12 months or longer?
YES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
NO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
REFUSED . . . . . . . . . . . . . . . . . . . . . . . . . 7
DON'T KNOW . . . . . . . . . . . . . . . . . . . . . . 9
BOX 1BB
CHECK ITEM PFQ.035:
IF SP AGE <= 15, CONTINUE.
OTHERWISE, GO TO END OF SECTION.
PFQ.040 Does {SP} receive Special Education or Early Intervention Services? 
YES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
NO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
REFUSED . . . . . . . . . . . . . . . . . . . . . . . . . 7
DON'T KNOW . . . . . . . . . . . . . . . . . . . . . . 9
BOX 1C
CHECK ITEM PFQ.045:
GO TO END OF SECTION.
PFQ.048 The next set of questions is about limitations caused by any long-term physical, mental or emotional problem
or illness.  Please do not include temporary conditions, such as a cold [or pregnancy].
Does a physical, mental or emotional problem now keep {you/SP} from working at a job or business?
YES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
NO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 (PFQ.056)
REFUSED . . . . . . . . . . . . . . . . . . . . . . . . . 7 (PFQ.056)
DON'T KNOW . . . . . . . . . . . . . . . . . . . . . . 9 (PFQ.056)
PFQ.050 {Are you/Is SP} limited in the kind or amount of work {you/s/he} can do because of a physical, mental or
emotional problem?  
YES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
NO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
REFUSED . . . . . . . . . . . . . . . . . . . . . . . . . 7
DON'T KNOW . . . . . . . . . . . . . . . . . . . . . . 9
PFQ.055 Because of a health problem, {do you/does SP} have difficulty walking without using any special equipment?
YES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
NO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
REFUSED . . . . . . . . . . . . . . . . . . . . . . . . . 7
DON'T KNOW . . . . . . . . . . . . . . . . . . . . . . 9
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PFQ.056 {Are you/Is SP} limited in any way because of difficulty remembering or because {you/s/he} experience{s}
periods of confusion?
YES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
NO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
REFUSED . . . . . . . . . . . . . . . . . . . . . . . . . 7
DON'T KNOW . . . . . . . . . . . . . . . . . . . . . . 9
BOX 1D
CHECK ITEM PFQ.058:
IF 'YES' (CODE 1) IN PFQ.048, PFQ.050, PFQ.055, OR
PFQ.056, GO TO PFQ.060.
OTHERWISE, CONTINUE.
PFQ.059 {Are you/Is SP} limited in any way in any activity because of a physical, mental or emotional problem?
YES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
NO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
REFUSED . . . . . . . . . . . . . . . . . . . . . . . . . 7
DON'T KNOW . . . . . . . . . . . . . . . . . . . . . . 9
BOX 1E
CHECK ITEM PFQ.059A:
IF SP AGE IS <=59 AND 'NO' (CODE 2) ENTERED IN PFQ.048,
PFQ.056 AND PFQ.059, GO TO PFQ.090.
OTHERWISE, CONTINUE.
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PFQ.060 The next questions ask about difficulties {you/SP} may have doing certain activities because of a health
problem.  By "health problem" we mean any long-term physical, mental or emotional problem or illness {not
including pregnancy}.  
By {yourself/himself/herself} and without using any special equipment, how much difficulty {do you/does SP}
have . . .
HAND CARD PFQ1
DO NOT INCLUDE TEMPORARY CONDITIONS LIKE PREGNANCY OR BROKEN LIMBS.
CAPI INSTRUCTION:  
IF PFQ.055 = '1' (YES), DO NOT DISPLAY 'B' OR 'C'.
IF SP FEMALE, DISPLAY 'NOT INCLUDING PREGNANCY'.
RESPONSES:  NO DIFFICULTY = 1, SOME DIFFICULTY = 2, MUCH DIFFICULTY = 3, 
UNABLE TO DO = 4, REFUSED = 7, DON'T KNOW = 9.
a. managing {your/his/her} money [such as keeping track of
{your/his/her} expenses or paying bills]? ____
b. walking for a quarter of a mile [that is about 2 or 3 blocks]? ____
c. walking up 10 steps without resting? ____
d. stooping, crouching, or kneeling? ____
e. lifting or carrying something as heavy as 10 pounds [like a
sack of potatoes or rice]? ____
f. doing chores around the house [like vacuuming, sweeping,
dusting, or straightening up]? ____
g. preparing {your/his/her} own meals? ____
h. walking from one room to another on the same level? ____
i. standing up from an armless straight chair? ____
j. getting in or out of bed? ____
k. eating, like holding a fork, cutting food or drinking from a glass? ____
l. dressing {yourself/himself/herself}, including tying shoes,
working zippers, and doing buttons? ____
m. standing or being on {your/his/her} feet for about 2 hours? ____
n. sitting for about 2 hours? ____
o. reaching up over {your/his/her} head? ____
p. using {your/his/her} fingers to grasp or handle small objects? ____
q. going out to things like shopping, movies, or sporting events? ____
r. participating in social activities [visiting friends, attending
clubs or meetings or going to parties]? ____
s. doing things to relax at home or for leisure [reading, watching
TV, sewing, listening to music]? ____
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BOX 1F
CHECK ITEM PFQ.066:
IF 'SOME DIFFICULTY' (CODE 2), 'MUCH DIFFICULTY' (CODE
3), OR 'UNABLE TO DO' (CODE 4) IN PFQ.060 A THROUGH S,
CONTINUE.
OTHERWISE, GO TO PFQ.090.
PFQ.067 What condition or health problem causes {you/SP} to have difficulty with or need help with {NAME OF UP TO
3 ACTIVITIES/these activities}?
HAND CARD PFQ2
ENTER ALL THAT APPLY UP TO 5 BUT DO NOT PROBE.
DO NOT ENTER 'OLD AGE' AS CONDITION -- IF OLD AGE IS REPORTED, PROBE FOR ANY OTHER
CONDITION.
CAPI INSTRUCTION:  
IF THE TOTAL NUMBER OF ITEMS CODED 'SOME DIFFICULTY' (CODE 2), 'MUCH DIFFICULTY' (CODE
3), OR 'UNABLE TO DO' (CODE 4) IN PFQ.060 A THROUGH S <=3, DISPLAY EACH ITEM NAME IN THE
TEXT OF QUESTION.  IF MORE THAN 3 ITEMS ARE CODED IN THIS MANNER DISPLAY "THESE
ACTIVITIES" IN THE TEXT OF QUESTION.
ARTHRITIS/RHEUMATISM . . . . . . . . . . . . 10
BACK OR NECK PROBLEM . . . . . . . . . . . 11
BIRTH DEFECT . . . . . . . . . . . . . . . . . . . .12
CANCER . . . . . . . . . . . . . . . . . . . . . . . . . .13
DEPRESSION/ANXIETY/EMOTIONAL 
   PROBLEM . . . . . . . . . . . . . . . . . . . . . . .14
OTHER DEVELOPMENTAL PROBLEM 
   (SUCH AS CEREBRAL PALSY) . . . . . . . 15
DIABETES . . . . . . . . . . . . . . . . . . . . . . . .16
FRACTURES, BONE/JOINT INJURY . . . . 17
HEARING PROBLEM . . . . . . . . . . . . . . . . 18
HEART PROBLEM . . . . . . . . . . . . . . . . . . 19
HYPERTENSION/HIGH BLOOD 
   PRESSURE . . . . . . . . . . . . . . . . . . . . . .20
LUNG/BREATHING PROBLEM . . . . . . . . . 21
MENTAL RETARDATION . . . . . . . . . . . . . 22
OTHER INJURY . . . . . . . . . . . . . . . . . . . .23
SENILITY . . . . . . . . . . . . . . . . . . . . . . . . .24
STROKE PROBLEM . . . . . . . . . . . . . . . . . 25
VISION/PROBLEM SEEING . . . . . . . . . . . 26
WEIGHT PROBLEM . . . . . . . . . . . . . . . . . 27
OTHER IMPAIRMENT/PROBLEM . . . . . . 28
REFUSED . . . . . . . . . . . . . . . . . . . . . . . . .77
DON'T KNOW . . . . . . . . . . . . . . . . . . . . . .99
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BOX 2
CHECK ITEM PFQ.068:
IF CODE 10-11 OR 13-28 IN PFQ.067, CONTINUE WITH LOOP
1.
OTHERWISE, GO TO PFQ.090.
LOOP 1:
ASK QUESTION PFQ.069 FOR EACH CONDITION
MENTIONED IN PFQ.067 (CONDITION: 10-11 OR 13-28).
PFQ.069 How long have you had {CONDITION 10-11 or 13-28}?
CAPI INSTRUCTION:  
IF CODE 28 IN PFQ.067, THE FILL SHOULD BE {THE OTHER CONDITION YOU MENTIONED}.
|___|___|___|
ENTER NUMBER (OF DAYS, WEEKS, MONTHS OR YEARS)
SINCE BIRTH 666
REFUSED 777
DON'T KNOW 999
ENTER UNIT
DAYS 1
WEEKS 2
MONTHS 3
YEARS 4
REFUSED 7
DON'T KNOW 9
BOX 3
END LOOP 1:
CYCLE ON NEXT CONDITION.
IF NO NEXT CONDITION, GO TO PFQ.090.
PFQ.090 {Do you/Does SP} now have any health problem that requires {you/him/her} to use special equipment, such
as a cane, a wheelchair, a special bed, or a special telephone?
YES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
NO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
REFUSED . . . . . . . . . . . . . . . . . . . . . . . . . 7
DON'T KNOW . . . . . . . . . . . . . . . . . . . . . . 9
PFQ.100 {Do you/Does SP} usually use any special eating utensils?
YES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
NO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
REFUSED . . . . . . . . . . . . . . . . . . . . . . . . . 7
DON'T KNOW . . . . . . . . . . . . . . . . . . . . . . 9
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PFQ.110 {Do you/Does SP} usually use any aids or devices to help {you/him/her} dress [such as button hooks, zipper
pulls, long-handled shoe horn, etc.]?
YES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
NO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
REFUSED . . . . . . . . . . . . . . . . . . . . . . . . . 7
DON'T KNOW . . . . . . . . . . . . . . . . . . . . . . 9
105
12/3/98 Questionnaire: Family
      Target Group:   #  Head of CPS Family
(Non-SP)
#  Head of CPS Family
Spouse (Non-SP)
DEMOGRAPHIC QUESTIONNAIRE
BOX 1A
RULES FOR ADMINISTERING THE DEMOGRAPHIC AND OCCUPATION SECTION OF
THE FAMILY QUESTIONNAIRE:
1. FOR THE PURPOSE OF ADMINISTERING THIS SECTION A SEPARATE
"FAMILY" IS DEFINED AS THE 'NHANES FAMILY' AS DESCRIBED
BELOW:
GROUP 1
# #EITHER AN INDIVIDUAL HOUSEHOLDER OR PRIMARY FAMILY.
# RELATED SUBFAMILY.
# SECONDARY INDIVIDUALS WHO ARE RELATED TO ANYONE
ABOVE
AS A PARTNER.
GROUP 2
# UNRELATED SUBFAMILIES.
# SECONDARY INDIVIDUALS WHO ARE RELATED TO THEM AS 
A PARTNER.
GROUP 3
# SECONDARY INDIVIDUALS WHO ARE NOT RELATED TO ANY 
INDIVIDUALS ABOVE.
NOTE:  FOSTER CHILDREN SHOULD BE CONSIDERED PART OF 
THE FOSTER PARENT'S FAMILY.
2. USING THE DEFINITION IN (1), ADMINISTER THE SECTION ONCE
TO EACH GROUP (NHANES FAMILY) IF THERE IS AT LEAST 1 SP IN
THE GROUP.
3. QUESTIONS SHOULD BE LOOPED THROUGH SEPARATELY FOR
EACH CPS FAMILY WITHIN THE GROUP:  HOUSEHOLDER, PRIMARY
FAMILY, RELATED SUBFAMILY, UNRELATED SUBFAMILY AND
SECONDARY INDIVIDUAL.
APPENDIX C
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BOX 1
LOOP 1:
ASK DMQ.110 - DMQ.140 AS APPROPRIATE FOR NON-SP HEAD OF CPS FAMILY
AND NON-SP SPOUSE (RELATIONSHIP OF "MARRIED" IN THE SCREENER) OF
HEAD OF CPS FAMILY.
# FIRST ASK DMQ.110, 130, AND 140 FOR NON-SP HEAD OF CPS FAMILY.
# NEXT, ASK DMQ.140 FOR NON-SP SPOUSE OF HEAD OF CPS FAMILY.
# EACH TARGET PERSON SHOULD BE ASKED THIS SECTION ONCE.
# IF NO NON-SP HEAD OF CPS FAMILY AND NON-SP SPOUSE, GO TO 
END OF SECTION.
DMQ.110 In what country {were you/was NON-SP Head} born?
_________________________________
ENTER COUNTRY NAME
REFUSED . . . . . . . . . . . . . . . . . . . . . . . . . 7
DON'T KNOW . . . . . . . . . . . . . . . . . . . . . . 9
CAPI INSTRUCTION:
FOLLOW THE BASIC FORMAT FOR DIETARY SUPPLEMENT LOOKUP.  ONLY ALLOW ENTRY OF 1
COUNTRY.  COUNTRY LOOKUP IN SP AND FAMILY QUESTIONNAIRES SHOULD WORK EXACTLY THE
SAME.
DMQ.115 PRESS BACKSPACE KEY TO START THE LOOKUP.
SELECT COUNTRY FROM CAPI COUNTRY LIST.
IF COUNTRY NOT ON LIST -- 
   PRESS BACKSPACE KEY TO DELETE ENTRY
   THEN TYPE '**' AND SELECT '** COUNTRY NOT ON LIST'.
PRESS ENTER TO ACCEPT SELECTION.
CAPI INSTRUCTION:
DISPLAY FIPS COUNTRY LIST.  INTERVIEWER SHOULD ONLY BE ABLE TO SELECT 1 COUNTRY FROM
THE LIST OR USE THE '**' OPTION TO ACCEPT THE ENTRY THEY KEYED.  REFUSED AND DON'T KNOW
OPTIONS SHOULD BE AVAILABLE TO THE INTERVIEWER AS THE F6 AND F5 KEYS.
BOX 2
CHECK ITEM DMQ.120:
IF ANY CODE OTHER THAN 'UNITED STATES', SKIP TO
DMQ.140.
DMQ.130 In what state {were you/was NON-SP HEAD} born?
ENTER 2 LETTER STATE  ABBREVIATION TO START THE LOOKUP.
SELECT STATE FROM CAPI STATE LIST.
PRESS ENTER TO ACCEPT SELECTION.
CAPI INSTRUCTION:
DISPLAY FIPS STATE LIST.  INTERVIEWER SHOULD ONLY BE ABLE TO SELECT 1 STATE FROM THE
LIST.  DON'T KNOW AND REFUSED SHOULD BE VALID OPTIONS.  THE STATE LOOKUP IN THE SP AND
FAMILY QUESTIONNAIRES SHOULD WORK EXACTLY THE SAME.
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DMQ.140 What is the highest grade or level of school {you have/NON-SP HEAD/NON-SP SPOUSE has} completed or
the highest degree {you have/he/she has} received?  
ENTER HIGHEST LEVEL OF SCHOOL.
NEVER ATTENDED/KINDERGARTEN 
  ONLY . . . . . . . . . . . . . . . . . . . . . . . . . . . 0
1ST GRADE . . . . . . . . . . . . . . . . . . . . . . . 1
2ND GRADE . . . . . . . . . . . . . . . . . . . . . . . 2
3RD GRADE . . . . . . . . . . . . . . . . . . . . . . . 3
4TH GRADE . . . . . . . . . . . . . . . . . . . . . . . 4
5TH GRADE . . . . . . . . . . . . . . . . . . . . . . . 5
6TH GRADE . . . . . . . . . . . . . . . . . . . . . . . 6
7TH GRADE . . . . . . . . . . . . . . . . . . . . . . . 7
8TH GRADE . . . . . . . . . . . . . . . . . . . . . . . 8
9TH GRADE . . . . . . . . . . . . . . . . . . . . . . . 9
10TH GRADE . . . . . . . . . . . . . . . . . . . . . .10
11TH GRADE . . . . . . . . . . . . . . . . . . . . . .11
12TH GRADE, NO DIPLOMA . . . . . . . . . . 12
HIGH SCHOOL GRADUATE . . . . . . . . . . . 13
GED OR EQUIVALENT . . . . . . . . . . . . . . . 14
SOME COLLEGE, NO DEGREE . . . . . . . . 15
ASSOCIATE DEGREE:  OCCUPATIONAL, 
  TECHNICAL, OR VOCATIONAL 
  PROGRAM . . . . . . . . . . . . . . . . . . . . . . .16
ASSOCIATE DEGREE:  ACADEMIC 
  PROGRAM . . . . . . . . . . . . . . . . . . . . . . .17
BACHELOR’S DEGREE (EXAMPLE:  BA, 
  AB, BS, BBA) . . . . . . . . . . . . . . . . . . . . .18
MASTER’S DEGREE (EXAMPLE:  MA, 
  MS, MEng, MEd, MBA). . . . . . . . . . . . . . 19
PROFESSIONAL SCHOOL DEGREE 
  (EXAMPLE:  MD, DDS, DVM, JD). . . . . . 20
DOCTORAL DEGREE (EXAMPLE:  
  PhD, EdD). . . . . . . . . . . . . . . . . . . . . . . .21
REFUSED . . . . . . . . . . . . . . . . . . . . . . . . .77
DON’T KNOW. . . . . . . . . . . . . . . . . . . . . .99
BOX 3
END LOOP 1:
# ASK DMQ.110-140 FOR NEXT TARGET PERSON (NON-SP HEAD)
ASK DMQ.140 FOR NEXT TARGET PERSON (NON-SP SPOUSE – 
RELATIONSHIP OF "MARRIED" IN THE SCREENER). 
IF NO NEXT PERSON, GO TO BOX 4.
BOX 4
LOOP 2:
ASK OCQ.150 - OCQ.380 FOR NON-SP HEAD IF AGE >= 16 AND NON-SP SPOUSE
(RELATIONSHIP OF 'MARRIED' IN THE SCREENER) OF HEAD IF NON-SP
SPOUSE AGE >= 16.
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OCQ.150 The next questions are about {your/NON-SP HEAD'S/NON-SP SPOUSE'S} current job or business.  Which of
the following {were you/was} {NON-SP HEAD/NON-SP SPOUSE} doing last week . . .  
working at a job or business,. . . . . . . . . . . 1 (OCQ.220)
with a job or business but not at work,. . . . 2
looking for work, or. . . . . . . . . . . . . . . . . . 3
not working at a job or business?. . . . . . . . 4 (OCQ.380)
REFUSED . . . . . . . . . . . . . . . . . . . . . . . . . 7
DON'T KNOW . . . . . . . . . . . . . . . . . . . . . . 9
OCQ.160 Did {you/NON-SP HEAD/NON-SP SPOUSE} do any work at a job or business at all last week (include unpaid
work in a family farm or business)?
YES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
NO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
REFUSED . . . . . . . . . . . . . . . . . . . . . . . . . 7 (OCQ.380)
DON'T KNOW . . . . . . . . . . . . . . . . . . . . . . 9 (OCQ.380)
BOX 5
CHECK ITEM DMQ.170:
IF OCQ.150 IS CODED '2', CONTINUE.
OTHERWISE, GO TO BOX 7.
OCQ.220 For whom did {you/NON-SP HEAD/NON-SP SPOUSE} work at {your/his/her} main job or business?  (What is
the name of the company, business, organization or employer?)
IF MORE THAN 1 JOB, PROBE FOR MAIN JOB.
_________________________________
ENTER NAME OF EMPLOYER
REFUSED . . . . . . . . . . . . . . . . . . . . . . . . . 7
DON'T KNOW . . . . . . . . . . . . . . . . . . . . . . 9
OCQ.230 What kind of business or industry is this?  (For example:  TV and radio management, retail shoe store, state
labor department, farm.)
_________________________________
ENTER NAME OF BUSINESS, JOB OR INDUSTRY
REFUSED . . . . . . . . . . . . . . . . . . . . . . . . . 7
DON'T KNOW . . . . . . . . . . . . . . . . . . . . . . 9
OCQ.240 What kind of work {were/was} {you/NON-SP HEAD/NON-SP SPOUSE} doing?  (For example:  farming, mail
clerk, computer specialist.)
_________________________________
ENTER NAME OF OCCUPATION
REFUSED . . . . . . . . . . . . . . . . . . . . . . . . . 7
DON'T KNOW . . . . . . . . . . . . . . . . . . . . . . 9
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OCQ.250 What {were/was} {your/NON-SP HEAD'S/NON-SP SPOUSE'S} most important activities on this job or
business?  (For example:  sells cars, keeps account books, operates printing press.)
_________________________________
ENTER NAME OF DUTIES
REFUSED . . . . . . . . . . . . . . . . . . . . . . . . . 7
DON'T KNOW . . . . . . . . . . . . . . . . . . . . . . 9
OCQ.260 Looking at the card, which of these best describes this job or work situation?
ASK IF NOT CLEAR
HAND CARD DMQ1
AN EMPLOYEE OF A PRIVATE COMPANY, 
BUSINESS, OR INDIVIDUAL FOR WAGES, 
SALARY, OR COMMISSION . . . . . . . . . . . 1
A FEDERAL GOVERNMENT EMPLOYEE . 2
A STATE GOVERNMENT EMPLOYEE . . . 3
A LOCAL GOVERNMENT EMPLOYEE . . . 4
SELF-EMPLOYED IN OWN BUSINESS, 
  PROFESSIONAL PRACTICE OR FARM . 5
WORKING WITHOUT PAY IN FAMILY 
  BUSINESS OR FARM . . . . . . . . . . . . . . . 6
REFUSED . . . . . . . . . . . . . . . . . . . . . . . . . 7
DON'T KNOW . . . . . . . . . . . . . . . . . . . . . . 9
BOX 6
CHECK ITEM DMQ.270:
GO TO BOX 7.
OCQ.380 What is the main reason {you/NON-SP HEAD/NON-SP SPOUSE} did not work last week?
TAKING CARE OF HOUSE OR FAMILY . . 1
GOING TO SCHOOL . . . . . . . . . . . . . . . . 2
RETIRED . . . . . . . . . . . . . . . . . . . . . . . . . 3
UNABLE TO WORK FOR HEALTH 
  REASONS . . . . . . . . . . . . . . . . . . . . . . . . 4
ON LAYOFF . . . . . . . . . . . . . . . . . . . . . . . 5
DISABLED . . . . . . . . . . . . . . . . . . . . . . . . 6
OTHER . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
REFUSED . . . . . . . . . . . . . . . . . . . . . . . . .77
DON'T KNOW . . . . . . . . . . . . . . . . . . . . . .99
BOX 7
END LOOP 2:
ASK OCQ.150 - OCQ.380 FOR NEXT TARGET PERSON (NON-SP HEAD OR NON-
SP SPOUSE - RELATIONSHIP OF "MARRIED" IN THE SCREENER).  
IF NO NEXT PERSON, GO TO END OF SECTION.
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3/7/00 Questionnaire: SP (Year 2)
Target Group: SPs 1+
MEDICAL CONDITION 
QUESTIONNAIRE
MCQ.010 Has a doctor or other health professional ever told {you/SP} that {you have/s/he/SP has} asthma?
CAPI INSTRUCTION:
IF SP AGE >= 12, DISPLAY SP NAME AND "S/HE":
IF SP AGE < 12, DISPLAY "YOU" AND SP NAME.
YES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
NO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 (MCQ.053)
REFUSED . . . . . . . . . . . . . . . . . . . . . . . . . 7 (MCQ.053)
DON'T KNOW . . . . . . . . . . . . . . . . . . . . . . 9 (MCQ.053)
BOX 1
CHECK ITEM MCQ.015:
IF SP'S AGE <= 19, CONTINUE.
OTHERWISE, GO TO MCQ.040.
MCQ.020 How old {were you/was SP} when {you were/s/he was} first told {he/she} had asthma?
IF LESS THAN 1 YEAR, ENTER 1
CAPI INSTRUCTION:
IF SP AGE >= 16, DISPLAY "WERE YOU" AND "YOU WERE".
IF SP AGE = 12-15, DISPLAY "WAS {SP}" AND "S/HE WAS".
IF SP AGE < 12, DISPLAY "WAS {SP}" AND "YOU WERE".
|___|___|___|
ENTER AGE IN YEARS
REFUSED . . . . . . . . . . . . . . . . . . . . . . . . .777
DON'T KNOW . . . . . . . . . . . . . . . . . . . . . .999
MCQ.030 {Do you/Does SP} still have asthma?
YES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
NO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 (MCQ.053)
REFUSED . . . . . . . . . . . . . . . . . . . . . . . . . 7 (MCQ.053)
DON'T KNOW . . . . . . . . . . . . . . . . . . . . . . 9 (MCQ.053)
MCQ.040 During the past 12 months, {have you/has SP} had an episode of asthma or an asthma attack?
YES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
NO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 (MCQ.053)
REFUSED . . . . . . . . . . . . . . . . . . . . . . . . . 7 (MCQ.053)
APPENDIX D
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DON'T KNOW . . . . . . . . . . . . . . . . . . . . . . 9 (MCQ.053)
MCQ.050 [During the past 12 months], {have you/has SP} had to visit an emergency room or urgent care center
because of asthma?
YES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
NO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
REFUSED . . . . . . . . . . . . . . . . . . . . . . . . . 7
DON'T KNOW . . . . . . . . . . . . . . . . . . . . . . 9
MCQ.053 During the past 3 months, {have you/has SP} been on treatment for anemia, sometimes called "tired blood"
or "low blood"?  [Include diet, iron pills, iron shots, transfusions as treatment.]
YES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
NO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
REFUSED . . . . . . . . . . . . . . . . . . . . . . . . . 7
DON'T KNOW . . . . . . . . . . . . . . . . . . . . . . 9
BOX 2
CHECK ITEM MCQ.055:
IF SP AGE < 2, GO TO MCQ.114.
IF SP AGE 2-3, GO TO MCQ.080.
IF SP AGE 4-19, CONTINUE.
IF SP AGE >= 20, GO TO MCQ.092.
MCQ.060 Has a doctor or health professional ever told {you/SP} that {you/s/he/SP} had attention deficit disorder?
CAPI INSTRUCTION:
IF SP AGE >= 16, DISPLAY "YOU" AND "YOU".
IF SP AGE = 12-15, DISPLAY SP NAME AND "S/HE".
IF SP AGE < 12, DISPLAY "YOU" AND SP NAME.
YES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
NO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
REFUSED . . . . . . . . . . . . . . . . . . . . . . . . . 7
DON'T KNOW . . . . . . . . . . . . . . . . . . . . . . 9
MCQ.080 Has a doctor or health professional ever told {you/SP} that {you were/s/he/SP was} overweight?
CAPI INSTRUCTION:
IF SP AGE >= 16, DISPLAY "YOU" AND "YOU WERE".
IF SP AGE = 12-15, DISPLAY SP NAME AND "S/HE".
IF SP AGE < 12, DISPLAY "YOU" AND SP NAME.
YES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
NO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
REFUSED . . . . . . . . . . . . . . . . . . . . . . . . . 7
DON'T KNOW . . . . . . . . . . . . . . . . . . . . . . 9
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BOX 2A
CHECK ITEM MCQ.081:
IF SP'S AGE = 4-15, CONTINUE.
IF SP AGE >= 16, GO TO MCQ.090.
OTHERWISE, GO TO MCQ.114.
MCQ.083 Has a representative from a school or a health professional ever told {you/SP} that {s/he/SP} had a learning
disability?
CAPI INSTRUCTION:
IF SP AGE >= 12, DISPLAY SP NAME AND "S/HE".
IF SP AGE < 12, DISPLAY "YOU" AND SP NAME.
YES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
NO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
REFUSED . . . . . . . . . . . . . . . . . . . . . . . . . 7
DON'T KNOW . . . . . . . . . . . . . . . . . . . . . . 9
BOX 3
CHECK ITEM MCQ.085:
IF SP'S AGE >= 6, CONTINUE.
OTHERWISE, GO TO MCQ.114.
MCQ.090 {Have you/Has SP} ever had chickenpox?
YES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
NO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
REFUSED . . . . . . . . . . . . . . . . . . . . . . . . . 7
DON'T KNOW . . . . . . . . . . . . . . . . . . . . . . 9
MCQ.092 {Have you/Has SP} ever received a blood transfusion?
YES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
NO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 (BOX 4)
REFUSED . . . . . . . . . . . . . . . . . . . . . . . . . 7 (BOX 4)
DON'T KNOW . . . . . . . . . . . . . . . . . . . . . . 9 (BOX 4)
MCQ.093 In what year did {you/SP} receive {your/his/her} first transfusion?
|___|___|___|___|
ENTER 4-DIGIT YEAR
BOX 4
CHECK ITEM MCQ.095:
IF SP'S AGE = 8-15, CONTINUE
IF SP'S AGE >= 20, GO TO MCQ.140.
OTHERWISE, GO TO MCQ.120.
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MCQ.100 Has a doctor or health professional ever told {SP} that {s/he} had hypertension, also called high blood
pressure?
YES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
NO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 (MCQ.120)
REFUSED . . . . . . . . . . . . . . . . . . . . . . . . . 7 (MCQ.120)
DON'T KNOW . . . . . . . . . . . . . . . . . . . . . . 9 (MCQ.120)
MCQ.110 Because of {SP's} high blood pressure [hypertension], is {he/she} currently taking medicine?
YES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
NO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
REFUSED . . . . . . . . . . . . . . . . . . . . . . . . . 7
DON'T KNOW . . . . . . . . . . . . . . . . . . . . . . 9
BOX 5
CHECK ITEM MCQ.112:
IF SP'S AGE >= 6, GO TO MCQ.120
OTHERWISE, CONTINUE
MCQ.114 Has {SP} ever been tested for lead poisoning?
YES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
NO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 (MCQ.120)
REFUSED . . . . . . . . . . . . . . . . . . . . . . . . . 7 (MCQ.120)
DON'T KNOW . . . . . . . . . . . . . . . . . . . . . . 9 (MCQ.120)
MCQ.117 How long has it been since {SP} was tested?  
IF LESS THAN 1 MONTH, ENTER 1 MONTH
|___|___|
ENTER NUMBER (OF MONTHS OR YEARS)
REFUSED . . . . . . . . . . . . . . . . . . . . . . . . .77
DON'T KNOW . . . . . . . . . . . . . . . . . . . . . .99
ENTER UNIT
MONTHS . . . . . . . . . . . . . . . . . . . . . . . . . . 1
YEARS . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
REFUSED . . . . . . . . . . . . . . . . . . . . . . . . . 7
DON'T KNOW . . . . . . . . . . . . . . . . . . . . . . 9
MCQ.120 During the past 12 months, {have you/has SP} had . . .
CAPI INSTRUCTIONS:
DISPLAY ITEMS A AND B IF SP AGE <= 3.
DISPLAY ALL ITEMS (A, B, C AND D) IF SP AGE = 4-15.
DISPLAY ITEMS A AND C IF SP AGE >= 16.
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RESPONSES:  YES = 1, NO = 2, REFUSED = 7, DON'T KNOW = 9.
a. hay fever? ____
b. 3 or more ear infections? ____
c. frequent or severe headaches, including
migraines? ____
d. stuttering or stammering? ____
BOX 6
CHECK ITEM MCQ.135:
IF SP'S AGE >= 2, CONTINUE.
OTHERWISE, GO TO END OF SECTION.
MCQ.140 {Do you/Does SP} have trouble seeing, even when wearing glasses or contact lenses, if {you/he/she} wear{s}
them?
YES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
NO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
REFUSED . . . . . . . . . . . . . . . . . . . . . . . . . 7
DON'T KNOW . . . . . . . . . . . . . . . . . . . . . . 9
BOX 7
CHECK ITEM MCQ.145:
IF SP'S AGE 6-19, CONTINUE.
IF SP'S AGE >= 20, GO TO MCQ.160.
OTHERWISE, GO TO END OF SECTION.
BOX 7A
CHECK ITEM MCQ.146:
IF SP AGE 8-11 AND SP IS FEMALE, CONTINUE.
OTHERWISE, GO TO MCQ.150.
MCQ.147 Have {SP's} periods or menstrual cycles started yet?
YES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
NO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 (MCQ.150)
REFUSED . . . . . . . . . . . . . . . . . . . . . . . . . 7 (MCQ.150)
DON'T KNOW . . . . . . . . . . . . . . . . . . . . . . 9 (MCQ.150)
MCQ.148 How old was {SP} when her periods or menstrual cycles started?
|___|___|
ENTER AGE IN YEARS
REFUSED . . . . . . . . . . . . . . . . . . . . . . . . . 7
DON'T KNOW . . . . . . . . . . . . . . . . . . . . . . 9
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MCQ.150 During the past 12 months, that is, since {DISPLAY CURRENT MONTH} of {DISPLAY LAST YEAR}, about
how many days did {you/SP} miss school because of an illness or injury?
IF NONE, ENTER 0
|___|___|___|
ENTER NUMBER OF DAYS
DID NOT GO TO SCHOOL . . . . . . . . . . . .666
REFUSED . . . . . . . . . . . . . . . . . . . . . . . . .777
DON'T KNOW . . . . . . . . . . . . . . . . . . . . . .999
BOX 8
CHECK ITEM MCQ.155:
IF SP AGE >= 16, GO TO MCQ.245.
OTHERWISE, GO TO END OF SECTION.
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MCQ.160 MCQ.170 MCQ.180 MCQ.190
Has a doctor or other health {Do you/Does SP} still . . . ? How old {were you/was SP} when Which type of arthritis was it?
professional ever told {you/SP} {you were/s/he was} first told 
that {you/s/he} . . . {you/s/he} . . .
CAPI INSTRUCTION:  
TEXT OF QUESTION SHOULD BE
OPTIONAL AFTER FIRST ITEM IS
READ.
a. had arthritis?
YES . . . . . . . . . . 1
NO . . . . . . . . . . . 2 (b)
REFUSED . . . . . 7 (b)
DON'T KNOW. . 9 (b)
had arthritis? RHEUMATOID ARTHRITIS . . . . . . . . . . . . 1
|___|___|___|
ENTER AGE IN YEARS
REFUSED . . . . . . . . . . . . . . . . . . . . . . . . 777
DON'T KNOW . . . . . . . . . . . . . . . . . . . . . 999
OSTEOARTHRITIS . . . . . . . . . . . . . . . . . . . 2
OTHER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
REFUSED . . . . . . . . . . . . . . . . . . . . . . . . . . 7
DON'T KNOW . . . . . . . . . . . . . . . . . . . . . . . 9
b. had congestive heart failure?
YES . . . . . . . . . . 1
NO . . . . . . . . . . . 2 (c)
REFUSED . . . . . 7 (c)
DON'T KNOW. . 9 (c)
had congestive heart failure?
|___|___|___|
ENTER AGE IN YEARS
REFUSED . . . . . . . . . . . . . . . . . . . . . . . . 777
DON'T KNOW . . . . . . . . . . . . . . . . . . . . . 999
c. had coronary heart disease?
YES . . . . . . . . . . 1
NO . . . . . . . . . . . 2 (d)
REFUSED . . . . . 7 (d)
DON'T KNOW. . 9 (d)
had coronary heart disease?
|___|___|___|
ENTER AGE IN YEARS
REFUSED . . . . . . . . . . . . . . . . . . . . . . . . 777
DON'T KNOW . . . . . . . . . . . . . . . . . . . . . 999
d. had angina, also called angina had angina, also called agina pectoris?
pectoris?
YES . . . . . . . . . . 1
NO . . . . . . . . . . . 2 (e)
REFUSED . . . . . 7 (e)
DON'T KNOW. . 9 (e)
|___|___|___|
ENTER AGE IN YEARS
REFUSED . . . . . . . . . . . . . . . . . . . . . . . . 777
DON'T KNOW . . . . . . . . . . . . . . . . . . . . . 999
e. had a heart attack (also called had a heart attack (also called myocardial
myocardial infarction)?
YES . . . . . . . . . . 1
NO . . . . . . . . . . . 2 (f)
REFUSED . . . . . 7 (f)
DON'T KNOW. . 9 (f)
infarction)?
|___|___|___|
ENTER AGE IN YEARS
REFUSED . . . . . . . . . . . . . . . . . . . . . . . . 777
DON'T KNOW . . . . . . . . . . . . . . . . . . . . . 999
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f. had a stroke?
YES . . . . . . . . . . 1
NO . . . . . . . . . . . 2 (g)
REFUSED . . . . . 7 (g)
DON'T KNOW. . 9 (g)
had a stroke?
|___|___|___|
ENTER AGE IN YEARS
REFUSED . . . . . . . . . . . . . . . . . . . . . . . . 777
DON'T KNOW . . . . . . . . . . . . . . . . . . . . . 999
g. had emphysema?
YES . . . . . . . . . . 1
NO . . . . . . . . . . . 2 (h)
REFUSED . . . . . 7 (h)
DON'T KNOW. . 9 (h)
had emphysema?
|___|___|___|
ENTER AGE IN YEARS
REFUSED . . . . . . . . . . . . . . . . . . . . . . . . 777
DON'T KNOW . . . . . . . . . . . . . . . . . . . . . 999
h. had a goiter?
YES . . . . . . . . . . 1
NO . . . . . . . . . . . 2 (i)
REFUSED . . . . . 7 (i)
DON'T KNOW. . 9 (i)
have a goiter? had a goiter?
YES . . . . . . . . . . 1
NO . . . . . . . . . . . 2
REFUSED . . . . . 7
DON'T KNOW. . 9
|___|___|___|
ENTER AGE IN YEARS
REFUSED . . . . . . . . . . . . . . . . . . . . . . . . 777
DON'T KNOW . . . . . . . . . . . . . . . . . . . . . 999
i. had another thyroid disease?
YES . . . . . . . . . . 1
NO . . . . . . . . . . . 2 (j)
REFUSED . . . . . 7 (j)
DON'T KNOW. . 9 (j)
have another thyroid disease? had another thyroid disease?
YES . . . . . . . . . . 1
NO . . . . . . . . . . . 2
REFUSED . . . . . 7
DON'T KNOW. . 9
|___|___|___|
ENTER AGE IN YEARS
REFUSED . . . . . . . . . . . . . . . . . . . . . . . . 777
DON'T KNOW . . . . . . . . . . . . . . . . . . . . . 999
j. was overweight?
YES . . . . . . . . . . 1
NO . . . . . . . . . . . 2 (k)
REFUSED . . . . . 7 (k)
DON'T KNOW. . 9 (k)
k. had chronic bronchitis?
YES . . . . . . . . . . 1
NO . . . . . . . . . . . 2 (m)
REFUSED . . . . . 7 (m)
DON'T KNOW. . 9 (m)
have chronic bronchitis? had chronic bronchitis?
YES . . . . . . . . . . 1
NO . . . . . . . . . . . 2
REFUSED . . . . . 7
DON'T KNOW. . 9
|___|___|___|
ENTER AGE IN YEARS
REFUSED . . . . . . . . . . . . . . . . . . . . . . . . 777
DON'T KNOW . . . . . . . . . . . . . . . . . . . . . 999
l have this liver condition? had this liver condition?
. had any kind of liver
condition?
YES . . . . . . . . . . 1
NO . . . . . . . . . . . 2
REFUSED . . . . . 7
DON'T KNOW. . 9
YES . . . . . . . . . . 1
NO . . . . . . . . . . . 2
REFUSED . . . . . 7
DON'T KNOW. . 9
|___|___|___|
ENTER AGE IN YEARS
REFUSED . . . . . . . . . . . . . . . . . . . . . . . . 777
DON'T KNOW . . . . . . . . . . . . . . . . . . . . . 999
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MCQ.200 {Have you/Has SP} ever been told by a doctor or other health professional that {you/s/he} had an ulcer, this
could be a stomach, duodenal or peptic ulcer? 
YES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
NO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 (MCQ.220)
REFUSED . . . . . . . . . . . . . . . . . . . . . . . . . 7 (MCQ.220)
DON'T KNOW . . . . . . . . . . . . . . . . . . . . . . 9 (MCQ.220)
MCQ.210 During the past 12 months {have you/has SP} had an ulcer?
YES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
NO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2
REFUSED . . . . . . . . . . . . . . . . . . . . . . . . . 7
DON'T KNOW . . . . . . . . . . . . . . . . . . . . . . 9
MCQ.220 {Have you/Has SP} ever been told by a doctor or other health professional that {you/s/he} had cancer or a
malignancy of any kind?
YES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
NO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 (MCQ.245)
REFUSED . . . . . . . . . . . . . . . . . . . . . . . . . 7 (MCQ.245)
DON'T KNOW . . . . . . . . . . . . . . . . . . . . . . 9 (MCQ.245)
MCQ.230 What kind of cancer was it?
ENTER UP TO 3 KINDS.  IF RESPONDENT OFFERS MORE THAN 3, ENTER 66 AS THE 4TH RESPONSE.
CAPI INSTRUCTIONS:
ALLOW UP TO 3 ENTRIES.
ALLOW 'MORE THAN 3 KINDS (CODE 66) ONLY AS 4TH ENTRY.
(        ) (        ) (        ) (        )
BLADDER . . . . . . . . . . . . . . . . . . . . 10
BLOOD . . . . . . . . . . . . . . . . . . . . . . 11
BONE . . . . . . . . . . . . . . . . . . . . . . . . 12
BRAIN . . . . . . . . . . . . . . . . . . . . . . . 13
BREAST . . . . . . . . . . . . . . . . . . . . . . 14
CERVIX (CERVICAL) . . . . . . . . . . . 15
COLON . . . . . . . . . . . . . . . . . . . . . . 16
ESOPHAGUS (ESOPHAGEAL) . . . 17
GALLBLADDER . . . . . . . . . . . . . . . . 18
KIDNEY . . . . . . . . . . . . . . . . . . . . . . 19
LARYNX/WINDPIPE . . . . . . . . . . . . 20
LEUKEMIA . . . . . . . . . . . . . . . . . . . . . .21
LIVER . . . . . . . . . . . . . . . . . . . . . . . . . .22
LUNG . . . . . . . . . . . . . . . . . . . . . . . . . .23
LYMPHOMA/HODGKINS' DISEASE. . 24
MELANOMA . . . . . . . . . . . . . . . . . . . . .25
MOUTH/TONGUE/LIP . . . . . . . . . . . . .26
NERVOUS SYSTEM . . . . . . . . . . . . . .27
OVARY (OVARIAN) . . . . . . . . . . . . . . .28
PANCREAS (PANCREATIC) . . . . . . . 29
PROSTATE . . . . . . . . . . . . . . . . . . . . .30
RECTUM (RECTAL) . . . . . . . . . . . . . .31
SKIN (NON-MELANOMA). . . . . . . . . . 32
SKIN (DON'T KNOW WHAT KIND). . 33
SOFT TISSUE (MUSCLE OR FAT) . . 34
STOMACH . . . . . . . . . . . . . . . . . . . . . .35
TESTIS (TESTICULAR) . . . . . . . . . . . 36
THYROID . . . . . . . . . . . . . . . . . . . . . . .37
UTERUS (UTERINE) . . . . . . . . . . . . . . 38
OTHER . . . . . . . . . . . . . . . . . . . . . . . . .39
MORE THAN 3 KINDS . . . . . . . . . . . . 66
REFUSED . . . . . . . . . . . . . . . . . . . . . .77
DON'T KNOW . . . . . . . . . . . . . . . . . . .99
BOX 9
LOOP 1:
ASK MCQ.240 FOR EACH TYPE OF CANCER (CODES 10-39 AND CODE 99)
ENTERED IN MCQ.230.
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MCQ.240 How old {were you/was SP} when {TYPE OF CANCER/cancer} was first diagnosed?
CAPI INSTRUCTIONS:
DISPLAY TYPE OF CANCER (CODE 10-39) ENTERED IN MCQ.230.
DISPLAY "CANCER " IF DON'T KNOW ENTERED IN MCQ.230.
|___|___|___|
ENTER AGE IN YEARS
REFUSED . . . . . . . . . . . . . . . . . . . . . . . . .777
DON'T KNOW . . . . . . . . . . . . . . . . . . . . . .999
BOX 9A
END LOOP 1:
ASK MCQ.240 FOR NEXT TYPE OF CANCER (CODES 10-39 AND CODE 99)
ENTERED IN MCQ.230.  
IF NO NEXT TYPE, CONTINUE WITH MCQ.245.
MCQ.245 During the past 12 months, that is since {DISPLAY CURRENT MONTH} of last year, about how many days
did {you/SP} miss work at a job or business because of an illness or injury {do not include maternity leave}?
CAPI INSTRUCTION:
DISPLAY "DO NOT INCLUDE MATERNITY LEAVE" ONLY IF SP IS FEMALE.
|___|___|___|
ENTER NUMBER OF DAYS
DOES NOT WORK . . . . . . . . . . . . . . . . . .666
REFUSED . . . . . . . . . . . . . . . . . . . . . . . . .777
DON'T KNOW . . . . . . . . . . . . . . . . . . . . . .999
BOX 10
CHECK ITEM MCQ.247:
IF SP AGE >= 20, CONTINUE.
OTHERWISE, GO TO END OF SECTION.
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MCQ.250 MCQ.260
Including living and deceased, were any of {SP's/
your} biological that is, blood relatives including
grandparents, parents, brothers, sisters ever told 
by a health professional that they had . . .
CAPI INSTRUCTION:
TEXT OF QUESTION SHOULD BE OPTIONAL, "[ ]'S,
AFTER FIRST TIME.
Which biological [blood] family member?
CODE ALL THAT APPLY
a. diabetes?
YES . . . . . . . . . . 1
NO . . . . . . . . . . . 2 (b)
REFUSED . . . . . 7 (b)
DON'T KNOW. . 9 (b)
MOTHER . . . . . . . . . . . . . . . . . . . . . . 1
FATHER . . . . . . . . . . . . . . . . . . . . . . 2
MOTHER'S MOTHER . . . . . . . . . . . . 3
MOTHER'S FATHER . . . . . . . . . . . . 4
FATHER'S MOTHER . . . . . . . . . . . . 5
FATHER'S FATHER . . . . . . . . . . . . . 6
BROTHER . . . . . . . . . . . . . . . . . . . . . 7
SISTER . . . . . . . . . . . . . . . . . . . . . . . 8
OTHER . . . . . . . . . . . . . . . . . . . . . . . 9
REFUSED . . . . . . . . . . . . . . . . . . . . .77
DON'T KNOW. . . . . . . . . . . . . . . . . .99
b. Alzheimer's disease?
YES . . . . . . . . . . 1
NO . . . . . . . . . . . 2 (c)
REFUSED . . . . . 7 (c)
DON'T KNOW. . 9 (c)
MOTHER . . . . . . . . . . . . . . . . . . . . . . 1
FATHER . . . . . . . . . . . . . . . . . . . . . . 2
MOTHER'S MOTHER . . . . . . . . . . . . 3
MOTHER'S FATHER . . . . . . . . . . . . 4
FATHER'S MOTHER . . . . . . . . . . . . 5
FATHER'S FATHER . . . . . . . . . . . . . 6
BROTHER . . . . . . . . . . . . . . . . . . . . . 7
SISTER . . . . . . . . . . . . . . . . . . . . . . . 8
OTHER . . . . . . . . . . . . . . . . . . . . . . . 9
REFUSED . . . . . . . . . . . . . . . . . . . . .77
DON'T KNOW. . . . . . . . . . . . . . . . . .99
c. asthma?
YES . . . . . . . . . . 1
NO . . . . . . . . . . . 2 (d)
REFUSED . . . . . 7 (d)
DON'T KNOW. . 9 (d)
MOTHER . . . . . . . . . . . . . . . . . . . . . . 1
FATHER . . . . . . . . . . . . . . . . . . . . . . 2
MOTHER'S MOTHER . . . . . . . . . . . . 3
MOTHER'S FATHER . . . . . . . . . . . . 4
FATHER'S MOTHER . . . . . . . . . . . . 5
FATHER'S FATHER . . . . . . . . . . . . . 6
BROTHER . . . . . . . . . . . . . . . . . . . . . 7
SISTER . . . . . . . . . . . . . . . . . . . . . . . 8
OTHER . . . . . . . . . . . . . . . . . . . . . . . 9
REFUSED . . . . . . . . . . . . . . . . . . . . .77
DON'T KNOW. . . . . . . . . . . . . . . . . .99
d. arthritis?
YES . . . . . . . . . . 1
NO . . . . . . . . . . . 2 (e)
REFUSED . . . . . 7 (e)
DON'T KNOW. . 9 (e)
MOTHER . . . . . . . . . . . . . . . . . . . . . . 1
FATHER . . . . . . . . . . . . . . . . . . . . . . 2
MOTHER'S MOTHER . . . . . . . . . . . . 3
MOTHER'S FATHER . . . . . . . . . . . . 4
FATHER'S MOTHER . . . . . . . . . . . . 5
FATHER'S FATHER . . . . . . . . . . . . . 6
BROTHER . . . . . . . . . . . . . . . . . . . . . 7
SISTER . . . . . . . . . . . . . . . . . . . . . . . 8
OTHER . . . . . . . . . . . . . . . . . . . . . . . 9
REFUSED . . . . . . . . . . . . . . . . . . . . .77
DON'T KNOW. . . . . . . . . . . . . . . . . .99
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e. osteoporosis or brittle bones?
YES . . . . . . . . . . 1
NO . . . . . . . . . . . 2 (f)
REFUSED . . . . . 7 (f)
DON'T KNOW. . 9 (f)
MOTHER . . . . . . . . . . . . . . . . . . . . . . 1
FATHER . . . . . . . . . . . . . . . . . . . . . . 2
MOTHER'S MOTHER . . . . . . . . . . . . 3
MOTHER'S FATHER . . . . . . . . . . . . 4
FATHER'S MOTHER . . . . . . . . . . . . 5
FATHER'S FATHER . . . . . . . . . . . . . 6
BROTHER . . . . . . . . . . . . . . . . . . . . . 7
SISTER . . . . . . . . . . . . . . . . . . . . . . . 8
OTHER . . . . . . . . . . . . . . . . . . . . . . . 9
REFUSED . . . . . . . . . . . . . . . . . . . . .77
DON'T KNOW. . . . . . . . . . . . . . . . . .99
f. high blood pressure or stroke before the age of 50?
YES . . . . . . . . . . 1
NO . . . . . . . . . . . 2 (g)
REFUSED . . . . . 7 (g)
DON'T KNOW. . 9 (g)
MOTHER . . . . . . . . . . . . . . . . . . . . . . 1
FATHER . . . . . . . . . . . . . . . . . . . . . . 2
MOTHER'S MOTHER . . . . . . . . . . . . 3
MOTHER'S FATHER . . . . . . . . . . . . 4
FATHER'S MOTHER . . . . . . . . . . . . 5
FATHER'S FATHER . . . . . . . . . . . . . 6
BROTHER . . . . . . . . . . . . . . . . . . . . . 7
SISTER . . . . . . . . . . . . . . . . . . . . . . . 8
OTHER . . . . . . . . . . . . . . . . . . . . . . . 9
REFUSED . . . . . . . . . . . . . . . . . . . . .77
DON'T KNOW. . . . . . . . . . . . . . . . . .99
g. heart attack or angina before the age of 50?
YES . . . . . . . . . . 1
NO . . . . . . . . . . . 2
REFUSED . . . . . 7
DON'T KNOW. . 9
MOTHER . . . . . . . . . . . . . . . . . . . . . . 1
FATHER . . . . . . . . . . . . . . . . . . . . . . 2
MOTHER'S MOTHER . . . . . . . . . . . . 3
MOTHER'S FATHER . . . . . . . . . . . . 4
FATHER'S MOTHER . . . . . . . . . . . . 5
FATHER'S FATHER . . . . . . . . . . . . . 6
BROTHER . . . . . . . . . . . . . . . . . . . . . 7
SISTER . . . . . . . . . . . . . . . . . . . . . . . 8
OTHER . . . . . . . . . . . . . . . . . . . . . . . 9
REFUSED . . . . . . . . . . . . . . . . . . . . .77
DON'T KNOW. . . . . . . . . . . . . . . . . .99
MCQ.270 Did {your/SP's} biological mother ever fracture her hip?
YES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
NO . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 (END OF SECTION)
REFUSED . . . . . . . . . . . . . . . . . . . . . . . . . 7 (END OF SECTION)
DON'T KNOW . . . . . . . . . . . . . . . . . . . . . . 9 (END OF SECTION)
MCQ.280 About how old was she when she fractured her hip (the first time)?
|___|___|___|   (END OF SECTION)
ENTER AGE IN YEARS
REFUSED . . . . . . . . . . . . . . . . . . . . . . . . .777
DON'T KNOW . . . . . . . . . . . . . . . . . . . . . .999
MCQ.290 Was she. . . .
under 50 years old, or. . . . . . . . . . . . . . . . 1
50 years old or older?. . . . . . . . . . . . . . . . 2
REFUSED . . . . . . . . . . . . . . . . . . . . . . . . . 7
DON'T KNOW . . . . . . . . . . . . . . . . . . . . . . 9
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The higher the functional capacity score, the higher the functional capacity. 
No PAD Group equation: 
FC = 0 +9.904 (male) –coef (age) + coef (abi) = 9.904 
PAD Group equation: 
FC = 0.188 + 4.795 (male) –coef (age) + coef (abi)= 4.983 
No PAD-PAD difference, males: 
9.904 – 4.983= 4.921 
No PAD Group equation: 
FP = 0+ -0.362 (male) –coef (age) + coef (abi) = -0.362 
PAD Group equation: 
FP = 0.782 + -0.453 (male) - coef (age) + coef (abi) = -0.329 
The No PAD-PAD group difference, males: 
-0.362 - -0.329 = -0.033 
FP: 
The higher the functional performance score, the worse the functional 
performance. 
The difference in functional performance between males and females is larger in 
the PAD group than the non-PAD group.  
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APPENDIX E 
STEPS FOR TABLE 4.8 CALCULATIONS
Group No PAD: 
FC intercept set to zero (default) 
FP intercept set to zero (default) 
FL for Age free to vary for FC (-0.454) 
FL for Age free to vary for FP (0.070) 
Group PAD:  
FC intercept free to vary (-16.925) 
FP intercept free to vary (-2.354) 
FL for age free to vary for FC (-0.231) 
FL for age free to vary for FP (0.114) 
Calculations: 
No PAD= 0 + fl*AGE 
PAD= -16.925+ fl*AGE	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APPENDIX F STEPS FOR 
TABLE 4.9 CALCULATIONS 
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